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ABSTRACT OF THE DISSERTATION
Mechanisms of Erythropoietin-induced Neuroprotection in: in-vivo and
in-vitro Models of Hypoxia Ischemia
by
Rhonda Andrea Souvenir
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, December 2011
Dr. Jiping Tang, Chairperson
Hypoxic ischemic brain injury (HIBI) is a common cause of neonatal mortality and
morbidity. Approximately 60 % of preterm babies and 2% of full term infants suffer from
asphyxia. Asphyxia related death accounts for approximately 23% of neonatal mortality
annually. Many therapeutic interventions show promise in the laboratory but fail in
clinics. A thorough understanding of mechanisms by which promising therapeutic
intervention confers its neuroprotection is necessary to promote smoother transitions
from bench to the bedside. Erythropoietin (EPO), a hematopoietic growth factor that
increases oxygen availability during hypoxia/ischemia is associated with cell survival and
neuroprotection in: in vivo and in vitro models of hypoxia ischemia. However these
studies hold limited clinical translations because the underlying mechanism remains
unclear and the key molecules involved in EPO-induced neuroprotection are still to be
determined. Thus the central aim of this proposal is: to determine the key
mediators of EPO-induced neuroprotection and the mechanisms by which this
occurs in: in vitro and in vivo models of hypoxia ischemia.
Two alternate pathways of EPO-induced neuroprotection were elucidated in vitro
using oxygen and glucose deprivation to mimic hypoxia ischemia. Our findings showed
that EPO treatment resulted in an upregulation of tissues inhibitor of matrix
metalloproteinase (TIMP)-1 and inhibition of hypoxia inducible factor (HIF-1) both of

xii

which subsequently decreased in matrix metalloproteinase (MMP)-9 and promoted
neuroprotection. MMP-9 inhibition was associated with neuroprotection in both
pathways thus, inferring that inhibition of MMP-9 is one of the primary mechanisms of
EPO-induced neuroprotection. We also observed that EPO-induced neuroprotection was
reversed by inhibition of TIMP-1 or prolyl hydroxylase (PHD)-2. This lends to the
conclusion that TIMP-1 and PHD-2 are the key mediators of EPO-induced
neuroprotection in: in vivo and in vitro models of hypoxia ischemia.
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Note: Most of this chapter is taken from a review paper currently in the submission
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Abstract
Stroke continues to be one of the leading causes of mortality and morbidity
nationwide with only few therapeutic options. Recombinant human erythropoietin
(rhEPO) showed promising results in animal studies, and in human neonates. However
rhEPO treatment proved to be ineffective and sometimes detrimental against
subarachnoid or ischemic stroke in adults. The purpose of this review was to elucidate
the critical non-hematopoietic function of EPO-induced neuroprotection in the different
stroke models. Major biomedical bibliographical databases (MEDLINE, ISI, and
Cochrane Library) were searched with use of major keywords such as erythropoietin,
stroke, neonatal hypoxia ischemia and multiple terms denoting components of EPO
signaling pathways. EPO activates common signaling pathways for both hematopoietic
and non hematopoietic functions. However, there are important distinctions in the
molecular mechanisms of EPO-induced neuroprotection depending upon the level of
EPOR expression, injury type and developmental stage of affected individuals. Both
high dose EPO treatment and long term therapy tends to initiate notable erythropoiesis,
coagulation and thrombosis. Thus in order to harness the beneficial non-hematopoietic
functions of EPO in stroke therapy, the dose and duration of EPO treatment needs to be
carefully optimized and potential side effects closely monitored.
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Introduction
Stroke is the altering of brain, blood supply either by the rupturing or obstruction
of a vessel (WHO). The manner in which the blood supply is interrupted determines if
the stroke is hemorrhagic or ischemic. Hemorrhagic strokes are less common but more
detrimental than ischemic strokes. Alternately, a hemorrhagic stroke could lead to an
ischemic stroke (ASA; WHO). Thus, we’ll focus primarily on cerebral ischemia. There
are two main categories of stroke: ischemia and hemorrhage can be further categorized
according to the region of the brain affected. Subarachnoid hemorrhage (SAH),
intracerebral hemorrhage (ICH), global ischemia, focal ischemia, neonatal hypoxia
ischemia are all modeled in laboratory animals and was shown to be attenuated by
erythropoietin treatment. Systemic administration of single or multiple doses of
recombinant Erythropoietin (EPO) pre- or post- insult was shown to confer
neuroprotection in subarachnoid hemorrhage (Alafaci et al., 2000; Grasso, 2001; Grasso
et al., 2002a; Grasso, 2004), intracerebral hemorrhage (Lee et al., 2006d; Grasso et al.,
2009b), global ischemia ((Sakanaka et al., 1998; Calapai et al., 2000; Catania et al.,
2002), focal ischemia (Bernaudin et al., 1999; Brines et al., 2000; Zhang et al., 2010a),
neonatal hypoxia-ischemia (Kumral et al., 2004; Kumral et al., 2003), tramautic brain
injury (Lu et al., 2005; Chen et al., 2007) and even spinal cord injury (Gorio et al., 2002) ,
Parkinson’s (Kanaan et al., 2006) and multiple sclerosis (Sattler et al., 2004). Thus, EPO
was hailed as the panacea in stroke therapy and rapidly advanced to clinical trials.
Clinical trials for the use of EPO in SAH treatment yielded inconclusive results
due to a small population size; but showed promising results in Phase I for the treatment
of neonatal HI and adult cerebral ischemia (Meyer et al., 2003). These findings served to
bolster confidence in EPO’s potential for stroke therapy and accelerated its advance into
Phase II clinical trial (McPherson & Juul, 2010b) Hence, it was a resounding blow to
EPO researchers and the stroke community at large when Ehrenreich and colleagues
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reported that EPO not only failed to improve injury but also promoted tumor formation
and reduced quality of life for stroke patients in a multicenter clinical trial (Ehrenreich et
al., 2009). The failure of EPO in Phase II/III clinical trials raised several questions: Was
the route of administration too traumatic? Was the potential seen in animal models
exaggerated? Were the proposed mechanisms of action not clear? Or is EPO, like its
primary regulator HIF-1 a biphasic molecule, that is beneficial or detrimental depending
on the dose and time of administration? EPO has been administered intravenously for
treatment of anemia over the past ten years with no major complication. Additionally
Taylor and colleagues showed that there were no difference in the prevalence of
thrombotic and hypertensive side between patients administered EPO intravenously
compared to subcutaneously (Taylor et al., 1994). Thus if the route of administration
affected the outcome it would have played a minor role in EPO’s failure in Phase II/III
clinical trial. A comprehensive review of EPO treatment in animal models of stroke with
Meta analysis still predicts that EPO should show positive result in stroke therapy
(Jerndal et al., 2010; Minnerup et al., 2009). Since two of the four critical questions were
previously answered we’ll focus on the critical non hematopoietic function of EPO and
the mechanisms by which EPO accomplishes these functions.

Hypoxia Ischemia
Cerebral ischemia is associated with impaired cerebral blood flow (CBF), skewed
pH and electrolyte balance and increased free radical formation, intracranial pressure
(ICP) and inflammation (Dearden, 1985). Reduced CBF limits energy availability and
forces the cell into anaerobic respiration, which creates an acidic environment and
shifting in the sodium, potassium, calcium equilibrium (Siesjo et al., 1985a; Siesjo et al.,
1985b). Hypoxia is the physiological point at which the demand for oxygen supersedes
the available oxygen supply thus forces the body/cells to drastically alter its O2
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expenditure. Hypoxia triggers anaerobic respiration which results in an increase in
acidity. Low oxygen or acidic environment results in an accumulation of HIF-1 in the
cytoplasm (Jelkmann, 2005; Semenza, 2000b; Semenza, 2000a).

Erythropoietin Regulation
Cerebral hypoxia ischemia promotes an accumulation of hypoxia inducible factor
1 (HIF)-1 in neurons. HIF-1 has over 70 targets genes most of which are up-regulated
in response to hypoxia (Zagorska & Dulak, 2004).HIF-1 downstream gene EPO is
upregulated during ischemia in the brain of most mammals (Prass et al., 2003a). The
expression of EPO and EPO-receptor (EPOR) is regulated by HIF. HIFs are
heterodimeric transcription factors consisting of alpha and beta subunits (Chandel et al.,
2000). HIF-1 and-2 shares 40% homology.HIF-2 has been shown to bind to the beta
subunit of HIF1 during hypoxia (Krieg et al., 2000). An accumulation of HIF-1 or HIF2 during hypoxia is tissue dependant. The specific HIF in neuronal tissue is still highly
debate. HIF-1 regulates both pro and anti-apoptotic genes. Thus it’s considered to be
biphasic (Halterman & Federoff, 1999). Previous studies have suggest that the an
accumulation of HIF-1 is beneficial in the up-regulation of vascular endothelial growth
factor (VEGF) (Mu & Chang, 2003), EPO (Prass et al., 2003b), glucose transporter-1
(GLUT-1), glycolytic enzymes (Jones & Bergeron, 2001). However the early increase in
HIF-1alsolead to up-regulation of detrimental genes BNIP3(Bruick, 2003), Nix (Sowers
et al., 2001), p53 and the caspases (Li et al., 2005b). Our unpublished findings show
that exogenous administration of EPO inhibits HIF-1 in a dose dependent manner. The
mechanism by which this occurs warrants further studies.
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Erythropoietin
EPO is a hematopoietic growth factor that stimulates red blood cell (RBC)
production and is released in response to low oxygen (Haroon et al., 2003; Siren et al.,
2001b; Siren et al., 2001a). EPO secretion switches from the liver in the fetus to the
kidney in adults and is the primary regulator of erythropoiesis in mammals (Dame et al.,
2004). EPO is a part of the hypoxic response element and a known downstream gene of
HIF-1. Under physiological conditions serum EPO levels ranges from 4-27 mU/mL
(Caro & Erslev, 1988). However during hypoxia ischemia or asphyxia associated
condition there is more than a hundredth folds increase in serum EPO; this in turn
increases circulating reticulocytes, oxygen carrying capacity of the blood and overall
tissue oxygenation (Siren et al. 2001b; Siren et al. 2001a). In addition to hematopoietic
tissue, EPOR expression was observed on ovarian (Masuda et al., 2000), testicular
(Magnanti et al., 2001; Kobayashi et al., 2002), intestinal, pancreatic, cardiovascular (Wu
et al., 1999c; Wu et al., 1999b; Wu et al., 1999a) and neuronal tissues (Liu et al., 1997;
Tsai et al., 2006). In addition to its hematopoietic functions EPO is also associated with
cellular differentiation, proliferation and inhibition of apoptosis (Brines et al. 2000;
Sakanaka et al. 1998; Sun et al., 2005). It prevents damage against mechanical trauma,
excitotoxins, and neuro-inflammation (Brines et al. 2000; Sakanaka et al. 1998; Sun et
al. 2005).Whether or not the non-hematopoietic functions of EPO are transmitted via the
same receptor and signaling pathway as the hematopoietic functions is heavily debated.
Casals-Pascual speculated that the erythroid functions are carried out via the
homodimer form of the EPOR whereas cellular proliferation, survival and differentiation
in non hematopoietic cells are carried out by the β-receptor subunit (βcR) which is a
heterodimer (Casals-Pascual et al., 2009). A clear understanding of EPO signaling in
hematopoietic and non-hematopoietic events is pertinent to the clinical future of EPO in
stroke therapy. Should two different isoforms of EPOR be identified, the signaling

6

pathway still presents a challenge because the current dogma states that EPO signals
via the Janus Kinase (JAK) -2 pathway and its downstream signaling pathway in both
events.

Signaling Pathways of Erythropoietin
It is believed that binding of EPO to EPOR promotes the phosphorylation of
receptor associated tyrosine kinase, JAK-2 (Lacombe & Mayeux, 1999; Constantinescu
et al., 1999). Phosphorylated JAK-2, phosphorylates cytosolic transcription factor, signal
transducers and activators of transcription (STAT) allowing for the transcription of
proteins such as: cytokines, growth factors, cell survival and differentiation factors (Ihle,
1995a; Ihle, 1995c; Shuai et al., 1992a; Kaplan & Di, 1996b).
Janus Kinases are a family of receptor associated tyrosine kinases which
phosphorylates the receptor it’s allied with (Ihle 1995a; Ihle 1995b).The specific receptor
recruits different signaling molecules such as STAT proteins 1-6 for phosphorylation
(Ihle, 1995b; Ihle, 1995d; Shuai et al., 1992b; Kaplan & Di, 1996a). The phosphorylated
protein is translocated to the nucleus where it binds to the promoter of the specific gene
and initiates transcription of that gene (Ihle 1995a; Ihle 1995b). Previous studies have
shown that EPO and other hematopoietic growth factors are associated with the JAK-2
tryosine kinase (Witthuhn et al., 1993). However, the specific STAT that is
phosphorylated by each growth factor differs. STAT-3 is associated with EPOR
activation (Kretz et al., 2005) whereas STAT-6 and STAT-4 are responds to interleukin
(IL)-4 (Kaplan 1996a) and IL-12 (Kaplan 1996b) respectively. STAT-5 one of the most
widely studies transcription factors is also associated with EPOR binding. Studies have
shown that EPO activated STAT-5 promotes the transcription of anti apoptotic gene
BCL-XL and activation of Ras mitogen activated protein kinase (MAPK), ERK-1/-2, and
PI3K/Akt pathways (Kilic et al., 2005). STAT-3 is associated with propagation of growth
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in mature neurons and cell survival (Cheng et al., 2011). Studies have shown that STAT3 binds to the promoter of sequences of TIMP-1, which is associated with cell survival,
growth and differentiation in the presence of EPO (Kadri et al., 2000; Bugno et al., 1995)
TIMPs are endogenous inhibitors of MMPs (Jiang et al., 2002; Baker et al.,
2002). They are a family of four secreted proteins (TIMPs 1-4) that function in
maintaining extracellular matrix homeostasis (Gomez et al., 1997; Stetler-Stevenson et
al., 1990). TIMP-1 and TIMP-2 are believed to promote cell proliferation and enhanced
erythroid activity (Kadri et al., 2000). Subsequently TIMP-1 a 28.5-kDa glycoprotein was
found to be regulated by EPO. EPO triggers an increase in both mRNA and protein
levels of TIMP-1 (Kadri et al., 2000). TIMP-1 forms a 1:1 complex with MMP-9 and
inhibits its proteinase activities. MMPs are a family of protein-degrading zinc dependant
endopeptidases. MMPs cleave most of the extracellular matrix (ECM) and are involved
in the breakdown and remodeling of many tissues and organs (Isaksen & Fagerhol,
2001; Szabova et al., 2005). Studies have shown an inverse correlation with MMP-9
expression and activity and cell survival (Kadri et al., 2000). The same pathways utilized
in hematopoietic cells via EPO to promote differentiation, maturation, and survivals of
erythroid cells are utilized during EPO-induced neuroprotection. Thus EPO-induced cell
survival is more dependent on EPOR expression that cell type.

Erythropoietin and the Brain
Endogenous EPO signaling has been studied in the development of the central
nervous system and in neuroprotection. Increased neuronal apoptosis was
demonstrated in EPO-null and EPOR-null mice (Yu et al., 2001; Yu et al., 2002). EPO
has been regarded as an important regulator of the differentiation of neural progenitor
cells (NPCs). The importance of EPOR expression and activation to the neuroprotective
effects of EPO has been demonstrated by Wang and colleagues (Wang et al., 2004;
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Wang et al., 2006). EPOR expression on NPCs seems necessary for NPCs
differentiation into mature neurons but less important in mature neurons. EPOR-null
mice exhibited significant lower levels of NPCs in the subventricular zone compared to
the wild-type counterparts. Transgenic mice (EPOR-/-) were less resistant to hypoxia
ischemia and exhibit defect in NPCs maturation and migration to the ischemic penumbra
(Tsai et al., 2006). In addition to its role in NPCs differentiation, maturation and migration
EPO and EPOR also play significant role in neuronal survival in the different stroke
models (Studer et al., 2000; Shingo et al., 2001).

Erythropoietin-induced Neuroprotection in-vitro
In vitro studies have shown that EPO is neuroprotective in cultured hippocampal
and cortical neurons against glutamate toxicity (Morishita et al., 1997), oxygen and
glucose deprivation (OGD) (Sinor & Greenberg, 2000) and chemically induced hypoxia
(Siren et al., 2001b). Primary neuronal cultures exposed to OGD were protected via
EPO administration in a dose and time dependent manner. EPO induced
neuroprotection in vitro was associated with suppression of Bad and upregulation of
JAK-2, STAT-5, PI3K, AKT and Bcl2 (Ruscher et al., 2002). In addition to the antiapoptotic properties of EPO antioxidant properties were also detected in cultures.
Studies have shown that EPO stabilizes mitochondrial membrane potential and
decrease ROS in Abeta (25-35)-induced neuronal toxicity in PC-12 cells, up-regulated
anti-apoptotic and down regulate pro-apoptotic proteins (Li et al., 2005a). The protective
effects of EPO were not limited to in vitro findings.

Erythropoietin-induced neuroprotection in Subarachanoid Hemorrhage
Despite the difference in pathophysiology, EPO was shown to be neuroprotective
in more than one animal models of hemorrhagic stroke. EPO was shown to reduce
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neuronal damage and S-100 expression in cerebrospinal fluid of SAH rabbits 24, 48 and
72 hours after insult. Decrease S-100 was correlated with improved neurological
outcome (Grasso et al., 2002). In a rat intracisternal blood injection SAH model, a single
low dose of EPO (400IU/Kg) was shown to improve mean arterial blood pressure and
cerebral blood flow autoregulation (Springborg et al., 2003) . Increase in CSF, EPO
expression, reduced neurological deficits, vasoconstriction and attenuation of
vasospasm was observed in EPO treated SAH white rabbits (Grasso et al., 2002b).
Previous studies have shown that EPO gene administration prompts an increase in
phospho endothelial nitric oxide synthase (eNOS) and phospho-AKT with a
corresponding decrease in eNOS. This finding infers that EPO confers neuroprotection
and reduce vasospasm by modulating phosphorylated AKT and eNOS in SAH
(Santhanam et al., 2005). Alternately it appears that the neuroprotective mechanism of
EPO is conserved between models.

Erythropoietin-induced neuroprotection in Intracerebral Hemorrhage
Neuroprotection from collagenase induced ICH in rats by EPO was associated
with reduced hematoma formation, edema, apoptosis and inflammation and improved
neurological outcomes (Lee et al., 2006; Grasso et al., 2009). The dose and form of
EPO did not appear to hamper its neuroprotective properties. Intraperitoneal
administration of 500 to 5000IU/kg of recombinant human (rHu) EPO or 1000IU/kg
Darbepoetin alfa conferred neuroprotection after ICH (Lee et al., 2006b; Grasso et al.,
2009a). The neuroprotection observed in ICH was correlated decrease caspase, 3, 8
and 9 activity, TNF and Fas ligand expression (Lee et al., 2006a; Grasso et al., 2009c).
There was also notable increase in STAT-3, pAkt , pERK and eNOS activity observed in
EPO treated ICH rats. This observation alludes to an overlap in the mechanisms of EPO
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induced neuroprotection with the other animal models of stroke such as neonatal HI,
global and focal ischemia and SAH.

Erythropoietin-induced neuroprotection in adult cerebral ischemia
EPO-induced neuroprotection in cerebral ischemia is associated with
neurogenesis, angiogenesis, oligodendrogenesis, and improved cerebral blood flow and
blood brain barrier integrity (Li et al., 2007; Chi et al., 2008; Zhang et al., 2010b).
Sakanaka et al. demonstrated that intraventricular infusion of EPO in a gerbil model of
forebrain ischemia decrease synapse degeneration and neuronal loss. The
neuroprotective effects of EPO infusion was rapidly reversed by the addition of a soluble
EPOR which enhance the ischemic core and total neuronal loss in the animals
(Sakanaka et al, 1998). EPO-induced neuroprotection in both transient and permanent
MCAO appeared to be associated with increased pSTAT-5, Bcl-xL, (X-linked inhibitor of
apoptosis protein) XIAP and decreased caspase 3 and 9 in neuronal tissue (Zhang et
al., 2006; Fan et al., 2006). The upregulation of STAT-5 and the pan inhibition of
caspase-3 and -9 appear to be conserved across the different stroke models.

Erythropoietin-induced neuroprotection in Neonates
Single or multiple doses of EPO administered pre- or post- HI was shown to
promote neuroprotection in a rat model of neonatal hypoxia ischemia (Sun et al., 2004);
(Kim et al., 2008). EPO-induced neuroprotection in neonatal rats is associated with
reduced inflammation, apoptosis, brain atrophy, caspase 3 and 9 and increase
expression of heat shock protein (HSP) 70 expression, JAK/STAT and TIMP-1 activity .
Previous studies on the anti-inflammatory properties of EPO-induced neuroprotection in
neonates showed that EPO inhibits/reduces cerebral expression of CD4+ and CD68+
cells interlukin (IL)-1 and tumor necrosis factor (TNF)  expression (Sun et al. 2005). In
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addition to the anti-apoptotic and anti-inflammatory properties, EPO was also shown to
stimulate progenitor cell proliferation in the dentate gyrus and subventricular zone of
hypoxic ischemic (HI) neonates (Fan et al., 2011). These finding along with positive
results in phase I/II clinical trial for EPO use in the treatment of neonatal hypoxic
ischemic brain injury offer a glimmer of hope for EPO in stroke therapy (McPherson &
Juul, 2010a)

Clinical Use of Erythropoietin in Stroke Therapy
Clinical trials in three different categories of stroke yielded divergent results.
Single center study in China revealed that intravenous administration of 250 IU/kg of
EPO thrice weekly for four weeks, significantly improved motor function in preterm
infants at six months after birth (He et al., 2008). Subsequent studies were then
conducted to determine the safety and efficacy of EPO used in neonates for the
treatment of hypoxic ischemic brain injury (HIBI). Two independent single center studies
revealed that high dose EPO improved neurodevelopment outcomes in very preterm
infants and was safe and effective in doses ranging from 1000-2500IU/Kg (Fauchere et
al., 2008; Juul et al., 2008). The dose was extrapolated to adults and yielded
inconclusive or negative results (Tseng et al., 2010); Ehrenreich et al. 2009).
Clinical analysis of the neuroprotective effects of EPO in SAH patients’ based on
age, sepsis and concomitant Statin use revealed that the presence of sepsis attenuate
EPO’s protection. Considering that sepsis is an attack on the hematopoietic system it is
not surprising that it is difficult to harness its non-hematopoietic function of EPO in the
presence of infection (Tseng et al., 2010). Harnessing the non-hematopoietic benefits of
EPO in stroke therapy is a delicate balancing act.
The past decade has shown a staggering number of failed clinical trials in stroke
research. Many therapeutic interventions show promise in the laboratory but failed in the
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clinics. Thus, a thorough understanding of mechanisms by which promising therapeutic
intervention confers its neuroprotection is necessary to promote smoother transitions
from bench to the bedside for EPO in stroke therapy
Thus the central aim of this proposal is: to determine the key mediators of
EPO-induced neuroprotection and the mechanisms by which this occurs in: invitro and in-vivo models of hypoxia ischemia. In support of this aim we formed the
following hypothesis: exogenous administration of erythropoietin confers
neuroprotection is dependent on its up-regulation of tissue inhibitor of matrix
metalloproteinasee (TIMP)-1 and inhibition of hypoxia inducible factor (HIF)-1.
This hypothesis is based on the following observations Firstly: Previous studies have
confirmed that EPO triggers an increase in both mRNA and protein levels of TIMP-1
(Kadri et al. 2000e). TIMP-1 forms a 1:1 complex with MMP-9 and inhibits its proteinase
activities. Increased MMP-9 mediated apoptosis thus, its inhibition is associated with
improved cell survival in both in vivo and in vitro model of hypoxia ischemia (Chen et al.
2009?; Jiang et al. 2002;Baker et al. 2002). Secondly: HIF-1 target genes such as
matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF),
cyclooxygenase (COX), nitric oxide synthase (NOS) and p53 plays a role in vascular
permeability, angiogenesis, inflammation and cell death. Previous studies have shown
that inhibition of HIF-1 is neuroprotective (Chen 2008). Additionally preliminary findings
in our lab indicate that EPO administration during hypoxia ischemia inhibits HIF-1
protein expression in a dose dependent manner. Based on these observations, two aims
are designed to test this hypothesis:
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Specific Aims
Specific Aim One
Determine if tissue inhibitor of matrix metalloproteinase (TIMP)-1 mediates EPOinduced neuroprotection in vivo and in vitro. Sub-aim 1A: is descriptive, it will
demonstrate that EPO is neuroprotective in both models. The correlation between
neuroprotection and increases in JAK-2/ STAT-3 and TIMP-1 activities and the
subsequent down-regulation of MMP-9 will be shown. The optimum dose of EPO will be
determined by cell death and infarction in vitro and in vivo respectively. JAK2 and STAT3 will be assessed by western blotting for the phosphorylated forms of the protein. MMP9 and TIMP-1 activity will be assessed by zymography and reverse zymography
respectively. Sub-Aim 1B: is mechanistic: we will investigate if pharmacological inhibition
of JAK-2 or TIMP-1 negates EPO induced neuroprotection during hypoxia ischemia in
vitro and in vivo. Neuroprotection will be assessed by cell death and infarct volume in
vitro and in vivo respectively.

Specific Aim Two
Determine the mechanism by which EPO regulates HIF -1 expression. Sub-aim:
2A is descriptive: We will profile the expression of HIF-1 and HIF -2 in response to
EPO treatment during OGD. HIF-1 and HIF-2 has 40% homology. HIF-2 has been
shown to bind to the beta subunit of HIF1 during hypoxia (Krieg et al., 2000b). Thus it is
necessary to profile both isoforms to determine if EPO is inhibiting both. Cell survival
during oxygen and glucose deprivation will be used to determine the optimum dose of
EPO. HIF-1 and HIF-2 protein expression and activity will be determined by western
blotting and reverse transcriptase polymerase chain reaction (RT-PCR) respectively. It is
hypothesized that both HIF-1 and not HIF-2 will decrease with EPO treatment.

14

Sub-aim 2B: is mechanistic and will determine the profile of HIF-1 alpha regulators ROS,
PHD-2 and VHL in EPO treatment of OGD cells. Two techniques dichlorofluorescein and
myeloperoxidase assay will be used to assess ROS production. Both PHD-2 and VHL
expression will be assessed by western blotting and RT-PCR. It is expected that there
will be an increase in PHD and VHL expression and a decrease in the generation ROS
in the EPO treated cells. Sub-aim 3C: Will verify the mechanism of EPO’s inhibition of
HIF-1α using pharmacological manipulations of EPOR and PHD2. EPOR receptor
antagonist EMP9 will be used to block the binding of EPO during OGD in EPO treated
cells. PHD2 inhibitor FG4095 will be used to inhibit PHD 2 expression in OGD cells. HIF1  and PHD-2 expression and activity and the generation of ROS in all groups will be
compared to control. It is expected that both EPOR antagonist and PHD-2 will negate
the neuroprotective effects of EPO as well as its inhibition of HIF-1.
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Figure 1.1. Schematic representation of the overall research proposal: the central
hypothesis and aims being studied
Aim 1 illustrated in green proposes that binding of exogenous rhEPO to its receptor
stimulates the phosphorylation of Janice Kinase 2 which in turn phosphorylates STAT-3.
The phosphorylated STAT-3 is then translocated to the nucleus where it initiates TIMP-1
transcription. The increase in TIMP-1 inhibits MMP-9 thereby promoting cell survival.
Aim 2 illustrated in orange shows the pathophysiological response to hypoxia ischemia
or oxygen and glucose deprivation. This aim proposes that treatment with exogenous
rhEPO inhibits HIF-1a. The possibility of direct or indirect inhibition via ROS or PHD-2
will be examined.
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Abstract
Previous studies have shown that erythropoietin (EPO) is neuroprotective in both
in vivo and in vitro models of hypoxia ischemia. However theses studies hold limited
clinical translations because the underlying mechanism remains unclear and the key
molecules involved in EPO-induced neuroprotection are still to be determined. This
study investigated if tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and if its
upstream regulator signaling molecule Janus kinase-2 (JAK-2) are critical in EPOinduced neuroprotection. Hypoxia Ischemia (HI) was modeled in-vitro by oxygen and
glucose deprivation (OGD) and in-vivo by a modified version of Rice-Vannucci model of
HI in 10-day-old rat pups.
EPO treated cells were exposed to AG490, an inhibitor of JAK-2 or TIMP-1
neutralizing antibody for 2 hours with OGD. Cell death, phosphorylation of JAK-2 and
signal transducers and activators of transcription protein (STAT)-3, TIMP-1 expression,
and matrix metalloproteinase-9 (MMP-9) activity were measured and compared with
normoxic group. Hypoxic ischemic animals were treated one hour following HI and
evaluated 48 hours after. Our data showed that EPO significantly increased cell survival,
associated with increased TIMP-1 activity, phosphorylation of JAK-2, STAT-3, and
decreased MMP-9 activity in vivo and in vitro. EPO’s protective effects were reversed by
inhibition of JAK-2 or TIMP-1 in both models. We concluded that JAK-2, STAT-3 and
TIMP-1 are key mediators of EPO-induced neuroprotection during hypoxia ischemia
injury.
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Abbreviations

EPO: Erythropoietin
HI: Hypoxia Ischemia
JAK: Janus Kinase
MMP: Matrix Metalloproteinase
NGF: Neuronal Growth Factor
OGD: Oxygen and Glucose Deprivation
STAT: Signal Transducer and Activator of Transcription
TIMP: Tissue Inhibitor of matrix Metalloproteinase
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Introduction
Asphyxia is the disruption of placental/ pulmonary gas exchange. It is associated
with hypoxemia, respiratory and systemic acidosis, which are linked to cerebral hypoxia
ischemia in neonates (Vannucci 2000). Erythropoietin (EPO), a hematopoietic growth
factor, with non-hematopoietic functions, is upregulated during hypoxia ischemia in the
brain of most mammals (Prass et al. 2003). Although the upregulation of endogenous
EPO is not enough to confer neuroprotection during hypoxia, it is able to turn on some of
the necessary pro-survival pathways (Shein et al. 2008). Previous studies have shown
that exogenous administration of EPO confers neuroprotection in both in vitro and in vivo
models of cerebral ischemia (Brines et al. 2000; Sakanaka et al. 1998; Sun et al. 2005).
Our understanding of the mechanism by which this occurs is still unfolding.
Physiologically, EPO binds to the EPO receptor (EPOR) and promotes cellular
differentiation, proliferation and inhibition of apoptosis (Brines et al. 2000; Sakanaka et
al. 1998; Sun et al. 2005). It also prevents damage against mechanical trauma,
excitotoxins, and neuro-inflammation (Brines et al. 2000; Sakanaka et al. 1998; Sun et
al. 2005).
Previous studies have shown that EPO and other hematopoietic growth factors
are associated with the Janus Kinase (JAK)-2 tyrosine kinases (Harpur et al. 1992;
Witthuhn et al. 1993). Janus Kinases are a family of receptor tyrosine kinases
associated with membrane receptors and are phosphorylated when specific ligands bind
to its receptor. JAK-2 kinases phosphorylate cytosolic transcription factors, signal
transducers and activators of transcription (STAT), allowing for the transcription of
proteins such as: cytokines, growth factors, cell survival and differentiation factors
depending on the ligand (Ihle 1995b; Ihle 1995a; Shuai et al. 1992; Kaplan et al. 1996).
STAT-3 and STAT-5 are both associated with the EPOR and are both activated by the
binding of EPO to its receptor (Ruscher et al. 2002; Toth et al. 2008). STAT-3, the more
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primordial STAT is highly associated with embryonic development. It is the less studied
of the EPOR activated STATs, and is shown to bind to the promoter sequence of the
tissue inhibitor of matrix metalloproteinase (TIMP) -1 gene (Bugno et al. 1995,
Dominguez et al. 2008). TIMP-1 is associated with erythroid cell survival, growth and
differentiation in the presence of EPO (Kadri et al. 2000; Bugno et al. 1995).
TIMPs are a family of four secreted proteins (TIMPs 1-4) that function in
maintaining extracellular matrix homeostasis (Gomez et al. 1997; Carmichael et al.
1986; Stetler-Stevenson 1990; Stetler-Stevenson et al. 1990). TIMPs are endogenous
inhibitors of matrix metalloproteinases (MMP), a family of protein-degrading zinc
dependant endopeptidases (Jiang et al. 2002; Baker et al. 2002). The delicate balance
between TIMPs and MMPs regulates extracellular matrix, receptor shedding and growth
factor bioavailability (Sternlicht & Werb, 2001). MMPs are important in embryonic
development, angiogenesis, wound healing, inflammation, cancer, and tissue
destruction. MMPs cleave most of the extracellular matrix (ECM) and are involved in the
breakdown and remodeling of many tissues and organs (Birkedal-Hansen et al., 1993;
Isaksen and Fagerhol, 2001). Because of its ability to degrade ECM, changes in the
MMP-9 to TIMP-1 ratio leads to excessive tissue degradation and cell death. The
delicate balance is usually altered during hypoxia leading to a significant increase in
MMPs secretion that is not proportional to that of TIMPs (Reynolds, 1996; Ejeil et al.,
2003; Andrian et al., 2007). Previous studies have confirmed that EPO triggers an
increase in both mRNA and protein levels of TIMP-1 (Kadri et al. 2000). TIMP-1 forms a
1:1 complex with MMP-9 and inhibits its proteinase activities. Increased MMP-9
mediated apoptosis thus, its inhibition is associated with improved cell survival in both in
vivo and in vitro model of hypoxia ischemia (Chen et al. 2008; Jiang et al. 2002; Baker et
al. 2002). Additionally, an inverse correlation with MMP-9 expression and activity and
erythroid cell survival has been shown (Kadri et al. 2000). However, this correlation was

30

not shown in non-hematopoietic cells such as neurons and the relevance of TIMP-1 in
EPO induced neuroprotection in vivo and in vitro is still to be elucidated.
In this study, we sought to determine whether TIMP-1 expression and antigelatinase activity are important in EPO induced neuroprotection during hypoxia
ischemia. Cerebral hypoxia ischemia was modeled in vitro by oxygen and glucose
deprivation (OGD) in PC12 cells and in vivo by permanent ligation of the right common
carotid artery followed by two hours of hypoxia in 10-day-old (P-10) rat pups (Zagorska
and Dulak 2004; Vannucci et al. 1999). We examined the expression of TIMP-1,
phosphorylated JAK-2 and STAT-3, as well as the activities of TIMP-1 and MMP-9 with
EPO treatment during OGD. We then investigated if pharmacological inhibition of JAK-2
or TIMP-1 negated EPO induced neuroprotection during hypoxia ischemia in vitro and in
vivo. The endpoints used to determine neuroprotection were cell death and infarct
volume in vitro and in vivo respectively.

Materials and Methods
Materials
Rat pheochromocytoma (PC-12) cells, fetal bovine serum (FBS) and horse
serum (HS) were obtained from ATCC (Manassas, VA). Procrit ©, human recombinant
erythropoietin was from Loma Linda University, Hospital Pharmacy (Loma Linda, CA.).
Neuronal growth factor (NGF) was from Alomone Laboratories Ltd. (Jerusalem, Israel).
Reverse zymography kit was from University of East Anglia, School of Biological
Sciences (Norwich UK). TIMP-1 neutralizing antibody was from AbD Serotec (Raleigh,
NC). AG490 was from Calibiochem (San Diego, CA). Rabbit phospho-STAT-3 (Tyr705)
(D3A7) monoclonal antibody was from Cell Signaling (Danvers MA). Rabbit phosphoJAK-2 (Tyr1007/1008) polyclonal antibody, rabbit anti- JAK-2 and mouse TIMP-1, clone
7-6C1 monoclonal antibody was obtained from Millipore Biosciences (Temecula, CA).
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Rabbit anti STAT-3, β−actin and all secondary antibodies were from Santa Cruz
Biotechnology. Cell death ELISA was from Roche Diagnostics (Indianapolis, IN). All
other reagents were obtained from Fisher Scientific (Tustin, CA).

Methods
Culturing and Differentiation of Cells
PC-12 cells passage 6 through 9 were used. Cells were grown on 100 mm2 polyD-lysine plates in Dulbeco's modified Eagle's medium (DMEM) supplemented with: 5%
FBS, 10% HS, 1% Penicillin/streptomycin , 25 mM glucose, 50 ng/ml NGF and
incubated at 37°C in 5% CO2 for 7 days as previously described (Greene 1976;Dickson
et al. 1986). .

Treatment of Cells
Normal media was replaced with glucose-free, supplemented DMEM with either
0,3,10 or 30 U/ml EPO. Cells were placed in a hypoxic chamber with less than 1%
oxygen for 2 hours (Agani et al. 2002). Treatment media was discarded and cells were
allowed to recover for 18 hours under normal conditions and collected for zymography,
reverse zymography, western blotting, trypan blue exclusion and cell death ELISA. Cells
were treated with 25 mM of AG490 during OGD for the inhibition of JAK/STAT and 3
μg/mL of TIMP-1 neutralizing antibody for inhibition of TIMP-1.

Protein extraction from PC-12 cells
Protein was extracted as previously described (Andrews and Faller 1991).
Briefly, cells were detached by scraping, rinsed with cold PBS, centrifuged and
supernatant discarded. Two hundred μL of radio-immuno-precipitation assay (RIPA)
lysis buffer [20 mM Tris, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% Na deoxycholate, 1 mM
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EDTA, and 0.1% sodium dodecyl sulfate (SDS)] supplemented with protease and
phosphatase inhibitor cocktails (Sigma-Aldrich, St. Louis, MO) were added and the
suspension shaken for 15 minutes at 4°C followed by centrifugation. Protein
concentrations were estimated by Bradford Assay (BioRad, Hercules, CA). Samples not
used immediately were aliquoted stored at -80°C for later use.

Cell Death Assay
Cell death was assessed by trypan blue exclusion and cell death ELISA
according to manufacturer’s protocol (Roche Diagnostics, Indianapolis, IN.) Briefly, cells
were collected by scraping. Sixteen μl of cell suspension mixed with 4 μl of trypan blue
and allowed to sit for 5 minutes. Cells were re-suspended and counted on a
hemocytometer thrice by two independent investigators. The formula used to calculate
percent cell death was as follows: (Trypan blue positive cells)]/ total cell counted) x 100.
The average of all six counts was used. There was an n of six per group.

Western Blotting
Western blotting was done as previously described (Dominguez et al. 2008). A
30μg sample of total protein per well with Laemmli sample buffer (62.5 mM Tris-HCl, pH
6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue and 5% β-mercaptoethanol) was
denatured at 90°C for 3-5 minutes prior to loading on a 4-12% Bis Tris gel (Biorad,
Hercules, CA). Gel was electrophoresed and protein transferred to nitrocellulose
membrane. The membrane was blocked with nonfat blocking grade milk (Biorad,
Hercules, CA) and probed with the appropriate dilutions of primary and secondary
antibodies to either JAK-2, pJAK-2, STAT-3, pSTAT-3, TIMP-1 or β−actin. Membranes
were washed and protein visualized using ECL Plus, Chemiluminescence (GE
Healthcare and Life Sciences, Piscataway, NJ). The optical densities of the bands were
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calculated with Image J, version 1.0 and normalized to β-actin which was used as a
loading control for all proteins studied.

Gelatin Zymography
Gelatin zymography was performed as previously described (Tang et al. 2004;
Wang et al. 2000; Wu et al. 2010). Briefly, 60 μg samples of protein extract were
prepared and separated by electrophoresis in 10% Tris-glycine gel with 0.1% gelatin as
substrate (Bio-Rad, Hercules, CA). The gel was re-natured for one hour and then
incubated with development buffer at 37°C for 48 hours. After development, the gel was
stained with 0.5% coomassie brilliant blue R-250 for one hour and then destained
appropriately. MMP activity was quantified. Optical densities were calculated with Image
J (version 1.0) software.

Reverse Zymography
Reverse zymography was performed according to manufacturer’s protocol.
Briefly, 60μg samples cell lysate (total protein) was mixed with (1:2 ratio) zymography
sample buffer [62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 4% SDS, 0.01% Bromophenol
Blue] (Bio-Rad, Hercules, CA), and loaded on a 15% gelatinase gel. Electrophoresis was
performed at 140V, and then gels were rinsed and incubated at 37oC for 48hours.
Stained withTIMP-1 and TIMP-2 were observed as dark bands as indicated by TIMPs
standard (East Anglia University, Norwich UK). TIMP-1 activity was quantified, and
optical densities were calculated with Image J, version 1.0.

Neonatal Hypoxic Ischemic Model
All animal research was conducted in accordance with protocols approved by
Loma Linda University Institutional Animal Care and Use Committee (IACUC). Time
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pregnant female Sprague-Dawley rats (n=5) (Harlan Laboratories, Indianapolis, IN) with
their dams were housed in light and temperature controlled environment with food and
water ad libitum for the duration of the study. Hypoxia ischemia (HI) was performed as
previously described (Calvert et al. 2002). Briefly, the right common carotid artery of
anesthetized (2.5% isoflourane in 30% O2 and 70% medical air) post-natal day 10 pups
(n=56) were permanently ligated, followed by one hour of rest and 2.5 hours of hypoxia
(8% O2 balance N2). The pups were returned to their respective dams and maintained at
ambient temperature for 24 hours. Animals were sacrificed under deep anesthesia at 48
hours post hypoxia and samples collected for 2, 3, 5-triphenyltetrazolium chloride
monohydrate (TTC) staining, imunohistochemistry, western blotting, zymography or
reverse zymography.

Intracerebral Ventricular Injection
Intracerebral ventricular injection was performed 1 hour prior to HI, as previously
described by Pang et al. (Pang et al. 2003). All drugs were concentrated so that animals
received no more than 0.5 μl of fluid in the ventricle. Dose response curves for both
TIMP-1 neutralizing antibody and AG490 were performed to determine the optimum
doses. The doses presented in this study were 300 ng per pup of TIMP-1 neutralizing
antibody and 15 μM of AG490. The vehicles used were IgG and 10% DMSO
respectively. Sham operated animals were given a needle stick using the same
coordinates as vehicle and treated animals to minimize/eliminated difference due to
surgical techniques.

Infarct Volume
Infarct volume was assessed by TTC staining as previously described (Yin et al.
2003). Briefly, pups were euthanized by isoflurane inhalation. Brain was immediately
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removed and sectioned into 2 μm slices. The slices were submerged in 2% TTC solution
for 5 minutes at 37°C and rinsed with cold phosphate buffered saline (PBS). Sections
were then fixed with 10% formaldehyde. The slices were photographed and analyzed
using Image J, version 1.0 software by different researchers both of whom were blinded
to the groups in this study. The following formula was used to calculated percent infarct
[(total area of contralateral hemisphere X 2) – (area of uninfarcted area of ipsilateral
hemisphere)]/ (total area of contralateral hemisphere X 2) for each slice.

Immunohistochemistry
Transcardial perfusion was performed as previously described (Hu et al. 1999;
Leonardo et al. 2010). Briefly, following anesthesia with 3.0% isoflurane for 3 to 5
minutes, pups were thoracotomized. A catheter was placed in the apex of the left
ventricle and an incision was made on the right atrium. The pups were perfused with 40
ml of PBS followed by 40 ml of 10% formalin. Collected brain tissues were first fixed in
10% formalin and then cryopreserved in 30% sucrose solution. The tissues were frozen
in optimal temperature cutting (OTC) solution (Fisher Scientific, Tustin CA) and
sectioned into 10 μm coronal slices by cryostat (CM3050S, Leica Microsystems,
Bannockburn, IL). The 10 μm sections were incubated with primary mouse anti- TIMP-1,
rabbit anti-MMP-9 (Millipore) or goat anti-MAP-2 (Santa Cruz Inc.) overnight at 4°C.
Fluorescence dye-conjugated secondary antibodies (Jackson Immuno Research, West
Grove, PA) fluorescein isothiocyanate (FITC; green fluorescence) donkey anti-mouse,
Texas red-conjugated donkey anti-rabbit IgG and AMCA-conjugated affinity pure donkey
anti-goat (Blue) were used. Sections were then observed under an Olympus B 51
microscope with a digital camera and Image-Pro plus software.
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Statistical Analysis
Data are presented as mean ± standard deviation. All data were validated using
one way ANOVA followed by Tukey or Dunn’s test. Statistical evaluation was performed
using Sigma Stat software version 3.5 (DUNDAS software LTD. Germany).

Results
Determining the Optimum Dose of Erythropoietin in vitro
To investigate the most effective dose of EPO during OGD, cells were treated
with 0,3,10 or 30 U/ml of EPO. After 18 hours of recovery, cell death was determined
quantitatively by trypan blue exclusion (figure 2.1.A, n=6) and qualitatively by ELISA
(figure 2.1.B, n=5). As compared with untreated, medium dose EPO 10 U/ml conferred
the most protection. Both low (3 U/ml) and high (30 U/ml) doses were ineffective in
minimizing cell death during OGD. Medium dose (10 U/mL) conferred significant
neuroprotection (p< 0.05) compared to the untreated group making this the most
effective dose (Figure 2.1.).
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Figure 2.1. The Optimum dose of Erythropoietin for neuroprotection during
Oxygen and Glucose Deprivation in vitro. (A) Cell viability as assessed by trypan blue
exclusion following HI and 18hrs of recovery. Data represent the mean (±SD): n = 6 in all
groups. (B) Cell viability as determined by cell death ELISA. Data represent the mean
(±SD): n = 5 in all groups. *P < 0.05 compared to untreated. # P< 0.05 compared to
10U/ml EPO group. 10U/mL conferred the most neuroprotection.
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Phosphorylation of JAK-2 and STAT-3 in vitro
To examine if phosphorylation of JAK-2 and STAT-3 are involved in EPO
induced neuroprotection we profile the expression of the phospho-proteins in the
presence and absence of their inhibitors and EPO during OGD in NGF differentiated PC12 cells. Figure 2:2 B shows a significant increase in JAK-2 phosphorylation (p<0.05) in
EPO treated group compared to normoxic, untreated and JAK inhibitor group (25 μM
AG490). The expression of phosphorylated STAT-3 was also significantly increased in
the 10U/mL EPO treated group (p<0.05) compared to that of all other groups Figure
2.2.C. This indicates EPO has an effect on both JAK-2 and STAT-3 phosphorylation
when used to treat NGF differentiated PC-12 cell during OGD.
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Figure 2.2. The profile of pJAK-2 and pSTAT-3 after the inhibition JAK-2 and TIMP1 during 2 hours of OGD. (A) Shows representative blots of pJAK-2, pSTAT-3 and the
b-actin used as the loading control. (B) JAK-2 phosphorylation in the presence of JAK-2
and TIMP-1 inhibitors.(c) STAT-3 phosphorylation in the presence of JAK-2 and TIMP-1
inhibitors. Data represent the mean (±SD): n = 5 in all groups. .* P< 0.05 compared to
untreated # P< 0.05 compared to the 10U/ml EPO treated group. Phosphorylation of
both JAK-2 and STAT-3 was increased with EPO treatment and reversed by inhibitors.
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TIMP-1 Expression and TIMP-1 and MMP-9 activity Following OGD in
Cultures
To determine the importance of TIMP-1 expression in EPO induced
neuroprotection, we profiled the expression and activity of TIMP-1 and its substrate
MMP-9 in the presence and absence of TIMP-1 inhibition and EPO during OGD. A
neutralizing antibody was used to inhibit TIMP-1 (3 μg/ml). Thus, it was not surprising
that although there was a visible increase in TIMP-1 expression figure 2.3.A row 1
representative blot and figure 2.3(b) densiometric quantification. It was expected that
only the biological activity and not the expression of TIMP-1 would be altered by the use
of a neutralizing antibody, which was shown in figure 2.3.A row 3 representative gel and
figure 2.3.C densiometric quantification .TIMP-1 activity was significantly increased in
EPO treated group (p<0.05) compared to the other groups. There was an inverse
correlation between TIMP-1 and MMP-9 activity figure 2.3.A representative gel and
figure 2.3.D densiometric quantification. MMP-9 activity was significantly decreased
(p<0.05) in the presence of EPO treatment compared to untreated.
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Figure 2.3. The Expression of TIMP-1 and Activity of TIMP-1 and MMP-9 in the
presence of JAK-2 and TIMP-1 inhibitors 18 hours after OGD. (A) Representative
blot (WB) of TIMP-1 and b-actin expression and coomassie blue stain of TIMP-1 activity
(dark bands) and MMP – activity (light bands), column 0 shows positive controls for
TIMP-1 and MMP-9. (B) Densitometric quantification of western blot for TIMP-1
expression. (C) Densiometric calculation of reverse zymography of TIMP-1 activity. (D)
Densiometric quantification of zymography of MMP-9 activity. Data represent the mean
(±SD): n = 6 in all groups represented in B,C and D. * P < 0.05 in all group compared to
untreated. # P < 0.05 compared to 10U/mL EPO treated group. EPO treatment
increased TIMP-1 activity and expression and reduced MMP-9 activity.
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Reversing EPO’s Neuroprotection
TIMP-1 or JAK-2 inhibitors were added to OGD cells in the presence or absence
of EPO to determine if these molecules were necessary for EPO-induced
neuroprotection. Neuroprotection was assessed by cell death assays. Inhibition of either
JAK-2 or TIMP-1 negated the neuroprotective effects of EPO Figure 2.4. Both trypan
blue exclusion Figure 2.4.A and cell death ELISA Figure 2.4.B showed a significant
increase in cell survival in the presence of EPO treatment compared to untreated and
inhibitor groups. EPO induced cell survival was attenuated in the presence of both
inhibitors.
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Figure 2.4. The effect of 2 hours of inhibition of JAK-2 and TIMP-1 during OGD on
cell death. Cell death assays showing the neuroprotective effects of EPO is reduced in
the presence of JAK-2 and STAT-3 inhibitors during OGD. Cell viability as assessed by:
(A) trypan blue exclusion (n=6) and (b) cell death ELISA (n=5) following HI and 18hrs of
recovery. Data represent the mean (±SD). * P< 0.05 compared to untreated. #P < 0.05
in all group compared to 10U/EPO treated group.

44

Phosphorylated JAK-2, Phosphorylated STAT-3 is Necessary for
Protection in vivo
To determine if the role of JAK-2 and STAT-3 in EPO-induced neuroprotection is
similar in animal to that observed in cultures, we profile the phosphorylation of JAK-2
and STAT-3 in the presence and absence of their inhibitors and EPO in the ipsilateral
cortex of neonatal hypoxic ischemic pups. Figure 2.5.C shows a significant increase in
JAK-2 phosphorylation (p<0.05) in sham, IgG +EPO and DMSO +EPO compared to IgG
vehicle and DMSO vehicle as well as TIMP-1 inhibitor with and without EPO. The
expression of phosphorylated STAT-3 was also significantly increased in the IgG+ EPO
and DMSO + EPO groups (p<0.05) compared to TIMP-1 inhibitor groups with and
without EPO and JAK-2 inhibitor groups with and without EPO, Figure 2.5.C. This
suggests a role for JAK-2 and STAT-3 in EPO-induced neuroprotection in vivo.
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Figure 2.5. The profile of phosphorylated JAK-2 and phosphorylated STAT-3 in the
ipsilateral cortex of the brain of HI rats (48 hrs) after inhibition of JAK2 or TIMP-1
(A) Shows a representative blots of pJAK-2, pSTAT-3 and the b-actin used as the
loading control. (B) JAK-2 phosphorylation in the presence of JAK-2 and TIMP-1
inhibitors. (C) STAT-3 phosphorylation in the presence of JAK-2 and TIMP-1 inhibitors.
Data represent the mean (±SD): n = 6 in all groups. .* P< 0.05 compared to untreated. #
P< 0.05 compared to the 10U/ml EPO treated group. EPO treatment increase the
phosphorylation of JAK-2 and STAT-3 and the inhibitors decreased both.
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TIMP-1 Expression and TIMP-1 and MMP-9 Activity in vivo 48 hours
after Hypoxia Ischemia
To determine the importance of TIMP-1 expression in EPO induced
neuroprotection, we profiled the expression and activity of TIMP-1, and its substrate,
MMP-9 in the presence and absence of TIMP-1 inhibition and EPO during HI. A
neutralizing antibody was used to inhibit TIMP-1 (300ng/pup). Neutralizing antibodies
binds to the active site of the protein thereby physically inhibiting the interaction of that
protein with its substrate. Thus, it was not surprising that although there was a visible
increase in TIMP-1 expression figure 2.6.A row 1 representative blot and figure 2.6.B
densiometric quantification there was no significant difference between the TIMP-1
inhibitors group and the IgG + EPO groups. . It was expected that only the biological
activity and not the expression of TIMP-1 would be altered by the use of a neutralizing
antibody, which was shown in figure 2.6.A row 3 representative gel and figure 2.6.A
densiometric quantification .TIMP-1 activity was significantly increased in the IgG +EPO
group (p<0.05) compared to the other groups. There was an inverse correlation between
TIMP-1 and MMP-9 activity figure 2.6.A row 4 representative gels and figure 2.6.D
densiometric quantification. MMP-9 activity was significantly decreased in the IgG +EPO
group (p<0.05) compared to IgG vehicle, EPO+ TIMP-1 inhibitor and EPO + JAK-2
inhibitor. Suggesting that both JAK-2 and TIMP-1 are involved in EPO induce
neuroprotection in vivo.
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Figure 2.6. The Expression of TIMP-1 and Activity of TIMP-1 and MMP-9 in the
presence of JAK-2 and TIMP-1 inhibitors 48 hours after HI in the brain. (A)
Representative blot (WB) of TIMP-1 and b-actin expression and coomassie blue stain of
TIMP-1 activity (dark bands) and MMP –9 activity (light bands), column 0 shows positive
controls for TIMP-1 and MMP-9. (B) Densitometric quantification of western blot for
TIMP-1 expression. (C) Densiometric calculation of reverse zymography of TIMP-1
activity. (D) Densiometric quantification of zymography of MMP-9 activity. Data
represent the mean (±SD): n = 6 in all groups represented in B, C and D. * P < 0.05 in all
group compared to IgG vehicle # P < 0.05 compared to IgG + EPO group. EPO
treatment increased TIMP-1 activity and expression and reduced MMP-9 activity.
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Co-localization of TIMP-1 and MMP-9, 48 hours after hypoxia
ischemia in vivo
To determine that the increase in TIMP-1 expression seen with EPO treatment in
vitro also occurred in vivo, we performed immunohistochemistry staining for TIMP-1 and
MMP-9 in HI animals with EPO using JAK-2 or TIMP-1 inhibitor (Figure 2.7). There was
an increase in TIMP-1 expression and a corresponding decrease in MMP-9 expression
in the cortex and hippocampus of animals and visible co-localization between TIMP-1
and MMP-9 in neurons indicating that there is interaction between the two. The optimum
dose of both JAK-2 inhibitor (AG490) and TIMP-1 neutralizing antibody was determined
by dose response curves (data not shown). The dose that reduced JAK-2 expression
and TIMP-1 activity without exacerbating injury was used. The optimum dose of AG490
used in vivo was 15 μM/pup. The dose of TIMP-1 neutralizing antibody used was 300
ng/pup. There was no visible difference between the inhibitor only groups and the
inhibitor with EPO groups so only the inhibitors plus EPO group were shown in the figure
2.7.
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Figure 2.7. TIMP-1 and MMP-9 expression in the brain of neonatal hypoxic
ischemic rats after inhibition of JAK-2 and TIMP-1. The expression of TIMP-1 (Texas
Red) and MMP-9 (green, FITC) in neurons (blue, AMCA) in the hippocampus (A, left
panel) and cortex (B, right panel) of neonatal HI animals treated with (5U/g) EPO. Merge
of TIMP-1 and MMP-9 with and without EPO are shown in the right panes. The colocalization of TIMP-1 and MMP-9 in neurons 48 hours after hypoxia ischemia in EPO
treated neonatal rats. Both inhibitors suppressed the upregulation of TIMP-1 in the
presence of EPO treatment.
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Inhibition of JAK-2 or TIMP-1 reverses EPO’s neuroprotection in vivo
EPO was effective in conferring neuroprotection in 10 day old neonatal hypoxic
ischemic pups. Similar to the in vitro results of EPO’s neuroprotective effects were
reversed by inhibition of either JAK-2 or TIMP-1 in vivo resulting in increased tissue
infarction figure 2.8.A representative brain slices, figure (2.8.A quantification of infarction.
Tissue infarction/cell death was significantly decreased in EPO treated animals without
inhibitor compared to both vehicle and inhibitor treated animals.
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Figure 2.8. Triphenyltetrazolium chloride (TTC) staining of brain tissue of neonatal
hypoxic ischemic pups after inhibition of JAK-2 and TIMP-1 (a) Representative
cross-sections from the brain of ischemic rat pups are depicted from anterior top) to
posterior (bottom). The white areas show the area of infarction for that pup at that
particular cross-sectional level. The mean (±SD) percent area of infarction is
represented on the graph in (b). (n=6 for sham) (n= 8 for all other groups). * P < 0.05 in
all group compared to IgG vehicle: #P < 0.05 in all group compared to 10U/EPO treated
group. Inhibition of JAK or TIMP-1 reverses EPO’s protection in vivo.
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Discussion
Our findings showed that the upregulation of TIMP-1 by exogenous EPO is
necessary for EPO-induced neuroprotection following neonatal hypoxia ischemia or
oxygen and glucose deprivation. We also found that EPO-induced neuroprotection was
associated with increased phosphorylation of the JAK-2 receptor, downstream signal
transducer STAT-3 and its transcription product TIMP-1 and significantly lower MMP-9
activity.
Erythropoietin is up-regulated during ischemia in the brain of most mammals
(Prass et al., 2003). EPO released in response to low oxygen promotes cellular
differentiation, proliferation and inhibition of apoptosis (Brines et al. 2000; Sakanaka et
al. 1998; Yoshimura 1998). Previous studies have shown that exogenous administration
of EPO is associated with neuroprotection in vivo and in vitro which was corroborate by
our findings (Sun et al. 2005; Ruscher et al 2002). The optimum dose of EPO needed to
produce these effects varies from cell type to cell type (Ruscher et al. 2002; Kadri et al.
2000; Renzi et al. 2002). Chan et al. showed that the optimum dose for JAK-2 activation
and MMP-9 inhibition and subsequent protection of cultured ischemic hearts was 5 U/mL
(Chan et al 2007). Interestingly EPO was shown to confer neuroprotection at a
significantly lower dose of 0.1 U/mL (Rusher et al. 2002). Our results showed that 10
U/mL of EPO were the optimum dose for neuroprotection in NGF differentiated PC-12
cells. We demonstrated the mechanism by which this occurred and the importance of
TIMP-1 activity in this protection. Several studies have shown that EPO is associated
with the family of JAK receptor tyrosine kinases. It is believed that binding of EPO to its
receptor EPOR promotes the phosphorylation of JAK-2 (Lacombe and Mayeux 1999a;
Lacombe and Mayeux 1999b; Constantinescu et al. 1999). The phosphorylated receptor
recruits different signaling molecules such as STAT proteins 1-6 for phosphorylation,
depending on the specific ligand bound to the receptor (Ihle 1995b; Ihle 1995a; Shuai et
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al. 1992; Kaplan et al. 1996b). The phosphorylated STAT is translocated to the nucleus
where it binds to the promoter of specific genes and initiates transcription of that gene
(Ihle 1995b; Ihle 1995a; Shuai et al. 1992; Kaplan et al. 1996b). The specific STAT that
is associated with EPO is still controversial. According to Chen et al STAT-5, one of the
most widely studies transcription factors, is associated with EPOR binding. STAT-5
promotes the transcription of anti-apoptotic gene BCL-XL and activation of Ras mitogen
activated protein kinase (MAPK), ERK-1/-2, and PI3K/Akt pathways (Chen et al. 2003;
Kilic et al. 2005). However, contrary to previous suggestion that STAT-3 is not involved
in EPO’s signaling; our results show that phosphorylated STAT-3 is involved in EPO
induced neuroprotection (Rusher et al 2002). This contradiction could possibly be
explained by the passage of cells and the age of the animals studied. In our studies we
used neonatal models of hypoxia ischemia. Neonatal animals are more likely to express
higher levels of STAT-3 than their adult counterparts because STAT-3 is a primordial
STAT associated with embryonic development (Murphya et al 2005.). Additionally,
STAT-3 is shown to be induced in response to injury in peripheral nerves. It is also
shown to be involved in axonal regeneration (Schwaiger et al. 2000; Sheu et al. 2000;
Qiu et al. 2005). Studies have shown that STAT-3 binds to the promoter sequences of
TIMP-1, which is associated with erythroid cell survival, growth and differentiation in the
presence of EPO (Kadri et al. 2000b; Bugno et al. 1995). Our study demonstrates that in
non-erythroid cells, EPO up-regulates TIMP-1 by phosphorylation of its transcription
factor STAT-3. Concordantly, there was a significant decrease in cell viability of EPO
treated cells if the JAK/STAT pathway was inhibited or there was a lower expression of
phosphorylated STAT-3. We did not study STAT-5 as the role of STAT-5 in EPO
induced neuroprotection was previously shown. We did not detect an induction of MMP2 during OGD in vitro and we observed that MMP-2 was constituently expressed in vivo
48 hours after HI thus we only focused on MMP-9.
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In this present study EPO treatment was accompanied by increased
phosphorylation of JAK-2, STAT-3 and TIMP-1 expression and activity. Kadri et al.
showed EPO induced increase in TIMP-1 expression in erythroid cells (Kadri et al.
2000b; Bugno et al. 1995). However, since EPO is shown to have different effects in non
hematopoietic cells, we needed to verify if TIMP-1 is important for EPO induced
neuroprotection. Our findings showed that TIMP-1 neutralizing antibody (figure 2.3.A and
2.3.B) did not significantly alter TIMP-1 expression which was not surprising.
Neutralizing antibody alters/inhibits the biological function/activities of
cells/receptors/proteins but does not change the protein levels. We observed an inverse
correlation between TIMP-1 and MMP-9 activity in the presence of EPO. This finding is
consistent with studies done by earlier authors which show similar correlations in
erythroid cells (Kadri et al. 2000b; Bugno et al. 1995). Our in vivo studies also reflect a
similar correlation between TIMP-1 and MMP-9 expression. There was a higher
expression of MMP-9 as shown by imunohistochemistry in the vehicle group compared
to EPO treated or sham operated animals. This finding seems to contradict previous
studies which showed that EPO increased MMP2/9 secretion into the media of
endothelial cells (Wang L. et al). This apparent disparity could be explained by the
difference in media and whole cell lysate. Additionally, endothelial cells make up a small
proportion of brain tissue and thus would not impact total MMP-9 activity. In vivo
inhibitions of either JAK-2 or TIMP-1 show a notable decrease in TIMP-1 expression
(immunohistochemistry) even with EPO treatment which we also saw with our TIMP-1
activity but not expression. Immunohistochemistry preserves protein structure and
integrity thus allowing for continued interaction between the active site of TIMP-1 and the
neutralizing antibody. However, during western blotting, the protein is run under
denaturing conditions thus allowing for separation of the neutralizing antibody from the
epitope. Thus it not surprising that visible TIMP-1 suppression was observed via
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immunohistochemistry in the TIMP-1 neutralizing antibody group that was not seen in
the western blot results. The interplay between EPO, TIMP and MMP appeared to be
occurring primarily in neuron, whether this interaction is autocrine or paracrine is still to
be elucidated.
The mechanism by which EPO confers its neuroprotection is still unfolding. In
2002, Ruscher et al observed that inhibition of the JAK/STAT pathway with
pharmaceutical inhibitor AG490 abolished EPO’s neuroprotection in an in-vitro model of
hypoxia ischemia (Ruscher et al. 2002). This was validated by our findings both in vitro
and in vivo. However the reversal of EPO’s neuroprotection by inhibition of TIMP-1 that
we observed was not previously shown in neuronal cell in vitro or in vivo. Thus, based
on this observation we concluded that in addition to the activity of the JAK/STAT
pathway TIMP-1 also plays a crucial role in EPO-induced neuroprotection in in-vivo and
in vitro models of hypoxia ischemia. This finding provides important information for
expanding our understanding of EPO as a potential treatment for neonatal hypoxicischemic brain injury.
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Abstract
Erythropoietin (EPO), a hematopoietic growth factor, increases oxygen
availability during hypoxia/ischemia and is associated with neuroprotection in: in vivo
and in vitro models of hypoxia ischemia. Hypoxia inducible factor (HIF)-1α is the central
transcriptional factor for regulation of oxygen associated genes in response to hypoxia.
EPO a downstream gene of hypoxia inducible factor was shown to inhibit HIF-1α in a
dose dependant manner in an in-vitro model of hypoxia ischemia. This study elucidates
the key mediator of EPO-induced HIF-1 inhibition and subsequent neuroprotection.
Oxygen and glucose deprivation was used to model hypoxia ischemia in vitro. Our
findings showed that EPO treatment resulted in an increase in prolyl hydroxylase (PHD)2 transcription and translation, inhibition of HIF-1 expression, ROS formation and
MMP-9 activity which resulted in neuroprotection. We also observed that EPO-induced
neuroprotection was reversed by siRNA silencing of PHD -2. This led to the conclusion
that PHD-2 is a key mediator of EPO-induced HIF-1 inhibition and subsequent
neuroprotection in an in vitro model of hypoxia ischemia.
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Abbreviations

EPO: Erythropoietin
HIF: Hypoxia Inducible Factor
MMP: Matrix Metalloproteinase
NGF: Neuronal Growth Factor
OGD: Oxygen and Glucose Deprivation
PHD: Prolyl Hydroxylase
ROS: Reactive Oxygen Species
VHL: Von Hippel Lindau
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Introduction
Stroke continues to be among the leading cause of mortality and morbidity; with
ischemic strokes accounting for more than 75% of all incidents (ASA, AHA). Despite
extensive stroke research there are few effective treatments available. Clinically, tissue
plasminogen activator (tPA) is commonly used. However the therapeutic window for tPA
is only three hours (Su et al., 2008). Several animal studies have shown promising
results for the use of stroke therapy however, recent clinical trials proved otherwise (Sun
et al., 2005); (Ehrenreich et al., 2009). Thus it’s imperative that we determine the key
mechanisms of EPO- induced neuroprotection. This will allow us to harness the
beneficial effects EPO treatment while minimizing the detrimental effects EPO therapy.
Cerebral hypoxia ischemia promotes an accumulation of hypoxia inducible factor
(HIF)-1 in neurons. HIF-1- is innate modulator of oxygen homeostasis in most
aerobes (Zagorska & Dulak, 2004). During conditions of hypoxia it initiates transcription
of VEGF (Mu & Chang, 2003), erythropoietin (EPO)(Prass et al., 2003), glucose
transporter-1 (GLU-1), glycolytic enzymes (Jones & Bergeron, 2001a), and several
prosurvival genes. However HIF-1 also prompts the transcription of proapoptotic genes
such as, MMP-9 (DeNiro et al., 2010), BNIP3(Bruick, 2003), Nix (Sowers et al., 2001),
p53 and the caspases (Li et al., 2005a).
Under normoxic condition HIF-1 is continuously synthesized and degraded
within 5 minutes by the ubiquitin–proteasome pathway (Huang et al., 1998; Kallio et al.,
1999; Salceda & Caro, 1997). HIF-1 first undergoes hydroxylation by prolyl hydroxylase
(PHD)-2 which allows it to interact with the product of the von Hippel-Lindau (VHL) tumor
suppressor gene (Ivan & Scaiano, 2003a; Jaakkola et al., 2001b; Lee et al., 2003). This
interaction allows for the poly ubiquitination and proteasome-dependent degradation of
HIF-1.
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PHDs have a strikingly low O2 affinity which is ideal for oxygen sensing (Epstein
et al., 2001d; Hirsila et al., 2003). Reduced oxygen or increased ROS allows for the
stabilization and accumulation of HIF-1 (Cash et al., 2007; Evans et al., 2005; Kamura
et al., 1999; Lisztwan et al., 1999; Stebbins et al., 1999) .The absence of oxygen or the
presence of ROS promotes the destabilization of PHD-2 (Cash et al., 2007a; Epstein et
al., 2001; Evans et al., 2005; Jones & Bergeron, 2001). HIF degradation pathways
require either hydroxylation or acetylation which is PHD-2 and oxygen dependant.
HIF- target gene, EPO, has been shown to modulate other target genes of HIF1such as matrix metalloproteinases (MMPs), vascular endothelial growth factor
(VEGF), cyclooxygenase (COX), nitric oxide synthase (NOS) and p53 (Wang et al.,
2008). However the effect of EPO on HIF-or its primary regulator PHD-2 warrants
further investigation. EPO was shown to stabilize mitochondrial membrane potential and
decrease ROS in Abeta(25-35)-induced neuronal toxicity in PC12 cells, up-regulated
anti-apoptotic and down regulate pro-apoptotic proteins (Li et al., 2005b). Alternately
ROS promotes HIF- accumulation. Therefore we hypothesized that EPO-induced
neuroprotection will reduce HIF-1 accumulation during hypoxia ischemia in vitro by
increasing PHD-2 and inhibiting ROS formation. We explored this hypothesis using
oxygen and glucose deprivation (OGD) of NGF differentiated PC-12 cells to model
cerebral hypoxia ischemia in vitro. The expression of HIF-1, HIF-2, PHD-2 and VHL,
as well as the accumulation of ROS in the presence and absence of EPO treatment in
during OGD were assessed. We then investigated if pharmacological inhibition of EPOR
or siRNA silencing of PHD-2 increases ROS accumulation and negates EPO-induced
neuroprotection during hypoxia ischemia in vitro. Neuroprotection was assessed by cell
death.
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Materials and Methods
Materials
The cell line (rat pheochromocytoma cells, PC-12 cells) and serum supplements
were obtained from ATCC (Manassas, VA.). Human recombinant erythropoietin (Procrit
©) was from Loma Linda University, Hospital Pharmacy (Loma Linda, CA.). Neuronal
growth factor (NGF) was from Alomone Laboratories Ltd. (Jerusalem, Israel). Rat
primary antibodies toward HIF-1 and HIF-2 were from ABD Serortec (Raleigh, NC).
HIF-PHD-2 antibody, β−actin and all secondary antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Gelatin gel, TRIZOL reagent, and primers were from
Invitrogen (Carlsbad, CA). Cell death ELISA was from Roche Diagnostics (Indianapolis,
IN). All other reagents were obtained from Fisher Scientific (Tustin, CA).

Methods
Culturing and Differentiation of Cells
Rat pheochromocytoma cells (PC-12 cells) (ATCC Manassas,VA) passage 6
through 9 were be use. Cells were grown in Dulbecco’s modified Eagle's medium
(DMEM)(Sigma Aldrich ST.Louis MO) with 5% Fetal bovine serum (FBS) and 10% horse
serum (HS)(ATCC Manassas,VA), 1% Penicillin/streptomycin and 25mM glucose as
previously described (Greene, 1976).Cells were incubated in 5% carbon dioxide
incubators at 37°C. At 75-80% confluence cells were sub-cultured on poly-L- lysine
coated dishes (BD San Diego CA) and allowed to attach for 24 hours. Neuronal growth
factor (NGF)(Alamones lab Israel) 50ng/mL was then added and cells allowed to
differentiate. . Approximately 75% of media was replaced every 2-3 days until 60-70%
of the cells were differentiated (Dickson et al., 1986).
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Treatment of Cells
Normal media was replaced with glucose-free, supplemented DMEM with either
0 or 10 U/ml EPO. Cells were then placed in a hypoxic chamber with less than 1%
oxygen for 2 hours (Agani et al., 2002). The media was then replaced with normal media
and cell allowed to recover for 18 hours. Cells were then collected for cell death assay,
western blotting, gelatin zymography or reverse transcriptase polymer chain reaction
(RT-PCR).

Protein extraction from PC-12 cells
Protein was extracted as previously described (Andrews and Faller 1991).
Briefly, cells were detached by scraping, rinsed with cold PBS, centrifuged and
supernatant discarded. Two hundred μL of radio-immuno-precipitation assay (RIPA)
lysis buffer [20 mM Tris, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% Na deoxycholate, 1 mM
EDTA, and 0.1% sodium dodecyl sulfate (SDS)] supplemented with protease and
phosphatase inhibitor cocktails (Sigma-Aldrich, St. Louis, MO) were added and the
suspension shaken for 15 minutes at 4°C followed by centrifugation. Protein
concentrations were estimated by Bradford Assay (BioRad, Hercules, CA). Samples not
used immediately were aliquoted stored at -80°C for later use.

Transfection
Cells were transfected Silencer® selected pre-designed siRNA to HIF-PHD-2
using Lipofectamine TM reagent according as previously described (Lee et al., 2008).
Briefly 24 hours prior to transfection cells were trypsinized and plated at a density of 2
x105 cells in polly D-lysine coated 6 well plates (BD biosciences) with Opti-MEM®
reduced serum media. Plus reagent and siRNA were allowed to incubate for 15 minutes
in a 1:1 ratio. Lipofectamine TM LTX reagent was then added and mixture incubated for
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25 minutes at room temperature. Reduced serum media was removed from cells and
replaced with media containing 5nMconcentration of siRNA complexed with
Lipofectamine TM. Plates were incubated for 24 hours and transfection efficiency
assessed and cells used for experiments.

Western Blotting
SDS-PAGE electrophoresis was done as previously described (Dominguez et al.
2008). A 40ug sample of total protein per well with a 1:1 ratio of sample buffer was
denatured at 95°C for 3-5 min prior to loading 4-12% Bis Tris gel (Bio Rad). Gels were
electrophoresed and protein transferred to nitrocellulose membrane. The membranes
were blocked with nonfat blocking grade milk (Biorad) and probed with the appropriate
dilutions of primary to HIF-1 (Abcam), HIF-2 (ABD Serotec), PHD-2 (Santa Cruz
Biotechnology, Santa Cruz, CA.), VHL (cell signaling Technologies) or loading control

-

actin (Santa Cruz Biotechnology). Membranes were washed and protein visualized using
ECL Plus, Chemiluminescence (GE Healthcare and Life Sciences, Piscataway, NJ). The
optical densities of the bands were calculated with Image J, version 1.0 and normalized
to β-actin which was used as a loading control for all proteins studied.

Gelatin Zymography
Gelatin zymography was performed as previously described (Tang et al. 2004;
Wang et al. 2000; Wu et al. 2010). Briefly, 60 μg samples of protein extract were
prepared and separated by electrophoresis in 10% Tris-glycine gel with 0.1% gelatin as
substrate (Bio-Rad, Hercules, CA). The gel was re-natured for one hour and then
incubated with development buffer at 37°C for 48 hours. After development, the gel was
stained with 0.5% coomassie brilliant blue R-250 for one hour and then destained for 18
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to 24 hours. MMP activity was visualized and photographed with BioRad Versa Doc
imager. Optical densities were calculated with Image J (version 1.0) software.

Assessment of Reactive Oxygen Species Formation
ROS was assessed immediately after OGD using OxiSelect™ ROS Assay Kit
(Cell Biolabs Inc. San Diego CA). The assay used 2, 7-Dichlorodihydrofluorescin
diacetate (DCFH-DA) and was performed according to manufacturer’s protocol. Briefly
cell were washed with Dulbecco’s phosphate buffer saline (DPBS) and incubated 1mM
of DCFH-DA in serum free media for 1 hour. Media was discarded and cells washed with
DPBS to remove unabsorbed DCFH-DA. DCF was then evaluated by spectrophotometry
at wavelength 405 nm and reference wavelength in a 96 well plate reader (BioRad,
Hercules CA).

Reverse Transcriptase Polymerase Chain Reaction
RNA was extracted using TRIZOL reagent (Invitrogen). DNA was synthesized
using SuperScript® First-Strand Synthesis System for RT-PCR (Invitrogen). PCR for
HIF-1 , PHD-2, VHL and internal standard GAPDH was performed with using the
following primers (forward 5’GGCTTTGTTATGTGCTAAC3’ and reverse
5’ACTTGATGTTCATCGTCCTC3’ for HIF-1), (forward
5’TAAACGGCCGAACGAAAGC3’ and reverse 5’GGGTTATCAACGTGACGGACA3’ for
PHD-2), (forward 5’ACAGGATGTGCAAGGACAAGTG3’ and reverse
5’TAGTCTGCAGCATTCCGTGAGT3’ for VHL) and (forward
5’ACCACAGTCCATGCCATCAC3’ and reverse 5’TCCACCACCCTGTTGCTGTA3’ for
GAPDH). Samples were cycled using a 2720 thermal cycler (Applied Biosciences).The
samples were denatured at 95°C for 5 minutes followed by 30 samples of amplification
for HIF-1, PHD-2 and VHL and 25 cycles for GAPDH. The amplication cycle consisted
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of 30 seconds denaturation at 94°C 30 seconds annealing at 56°C, 1 minute extension
at 72°C and a final extension of 5 minutes at 72°C. Samples were electrophoresed on
2% agarose gel with 0.5ug/mL etidium bromide. Gels were visualized under UV light
and photographed, and optical densities of the bands were analyzed with Quantity One
software (Bio-Rad).

Cell Death Assessment
Cell death was also determined using an Cell Death ELISA kit from Roche
Diagnostics (Indianapolis, IN) according to manufacturer’s instruction. Briefly the
supernatant of lysed cells was conllected and the concentration of mono- and
oligonucleosomes present in whole cell lysate using an ELISA kit. The concentration
was determined by spectrophotometry at wavelength 405nm with a reference
wavelength of 495nm using a 96 well plate reader (BioRad, Hercules CA).

Statistical Analysis
Data are presented as mean ± standard deviation. All data were validated using
one way ANOVA followed by Tukey or Dunn’s test. Statistical evaluation was performed
using Sigma Stat software version 3.5 (DUNDAS software LTD. Germany).
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Results
Determining if both HIF-1 and HIF-2 are Inhibited by EPO
Treatment
To determine if the reduction of HIF-1 expression we observed was a result of
an upregulation of HIF-2, we evaluated the expression of both HIF-1 and HIF-2
following OGD in NGF-differentiated PC-12 cells. HIF-1 expression was significantly
lower (p<0.5) in EPO treated cells compared to untreated cell figure 3.1.B. However HIF2 expression remained relatively unchanged via EPO treatment figure 3.1.C. Thus,
suggesting that HIF-1 is the more prevalent HIF during OGD in PC-12 cells.
Consequently a significant increase (p< 0.5) in PHD-2 expression was also observed in
the EPO treated group compared to normoxic and untreated group.
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Figure 3.1. The profile of HIF-1, HIF-2, and PHD-2 following 2 hours of OGD. (A)
A representative image of a western blot of HIF-1, HIF-2, PHD-2 and the -actin as
the loading control (B) Densiometric quantification of HIF-1 expression. (C) HIF-2
expression following EPO treatment. (D) PHD-2 expression following OGD. Data
represent mean (± SD) n=6 in all groups. *P<0.05 compared to 10U/ml EPO treated
group. HIF-1 but not HIF-2 expression was altered in the presence of EPO treatment.
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The Profile of the Extracellular (media) pH and Electrolytes Following
OGD
To determine if the change in HIF-a expression was mediated by a change in pH
and electrolytes we evaluated the pH, calcium and potassium of the media.We
hypothesized that intracellular changes in pH and electrolytes would be reflected in the
media since it is an artificial representation of the extracellular fluid. The pH was
unaffected by either OGD or EPO treatment figure 3.2.A. OGD prompted an increase in
extracellular calcium which was unaltered by EPO treatment figure 3.2.B. Hypoxia also
led to a modest increase in extracellular potassium in all groups except 10U/mL EPO
and control siRNA. Thus 10U/mL EPO treated group was significantly (p<0.05) higher
than normoxia but significantly lower (p<0.05) that all other groups except control siRNA
group figure 3.2.C.
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Figure 3.2. The pH, calcium and potassium content in the media following OGD.
(A) The pH of the media following 2 hours OGD with and without EPO treatment. (B) The
calcium present in the media following 2 hours OGD with and without EPO treatment.
(C) The calcium present in the media following 2 hours OGD with and without EPO
treatment. Data represent the mean and (± SD) n=6 in all groups. *P<0.05 compared to
10U/ml EPO treated group. #P<0.05 compared to normoxia. EPO treatment had no
effect on media pH or calcium.
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The Effect of EPO and PHD-2 Inhibition on ROS Formation and HIF1 and PHD-2 Expression
The primary mediators of HIF- expression are ROS and hypoxia. Therefore we
determined the consequence of EPO treatment on ROS formation in the presence of an
EPOR-Fc chimera which competitively binds to EPO thereby preventing it interaction
with the naïve EPOR and a PHD-2 siRNA. Transfection increases the porusness of the
cell membrane and is of itself an form of injury thus its not surprising that the basal levels
in the siRNA control group is higher that that of the untreated groups. The formation of
ROS was enhanced during OGD in all groups except the 10U/mL group and the control
siRNA +EPO group figure 3.3.B. Accordingly HIF-1 expression was positively
correlated with ROS formation. Elevated in all of the groups exhibiting high ROS
(p<0.05) and decreased in EPO treated groups figure 3.3.C. Conversely PHD-2
expression was inversely correlated with ROS formation and HIF-1 expression. PHD-2
expression was notably increased in 10U/mL group (p<0.05) and compared to
untreated, EPOR-Fc chimera, control siRNA, PHD-2 siRNA and PHD-2 siRNA + EPO
figure 3.3.D. This suggests that EPO either directly or indirectly alters ROS formation,
HIF-1 and PHD-2 expression when used with NGF-differentiated PC-12 cells.
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Figure 3.3. ROS formation, HIF-1 and PHD-2 expression in the presence of EPO
and PHD-2 inhibition. (A) Shows a representative blot of HIF-1, PHD-2 and the
loading control -actin. (B) ROS formation during OGD in the presence of inhibitors. (C)
HIF-1expression after OGD in the presence of inhibitors. (D) PHD-2 expression in after
OGD in the presence of inhibitors. Data represent the mean and (± SD) n=6 in all
groups. *P<0.05 compared to 10U/ml EPO treated group. Inhibition of EPO or PHD-2
enhanced HIF-1 expression and ROS formation
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Determining the Effects of EPO Treatment on mRNA Levels of HIF1, PHD-2 and VHL
Changes in protein expression are not always indicative of transcriptional
changes. Thus to determine if the changes we observed in HIF-1 and PHD-2
expression with EPO treatment and inhibitor were at the transcription or the translational
levels we did RT-PCR for these protein figure 3.4. Silencing of PHD-2 via siRNA
triggered a significant increase (p<0.05) in HIF-1transcription compared to 10U/mL
EPO group. On the contrary competitive inhibition of EPO did not affect HIF-1
transcription with and without EPO treatment figure 3.4.B. Alternately either inhibition of
EPOR or silencing of PHD-2 significantly lowered mRNA levels of PHD-2 figure 3.4.C.
Downstream effecter of HIF-1 degradation VHL appeared unaffected by EPO treatment
as well as inhibition of EPO or PHD-2, figure 3.4.E. This observation alluded to PHD-2
as one of the primary effecter of HIF-1 inhibition and subsequent neuroprotection in
NGF-differentiated PC-12 cells.
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Figure 3.4. mRNA levels of HIF-1, PHD-2 and VHL in the presence of EPO and
PHD-2 inhibition. (A) Shows representative gel of HIF-1, PHD-2 and the
housekeeping gene gapdh. (B) HIF-1 mRNA expression after OGD in the presence of
inhibitors. (C) PHD-2 mRNA expression in after OGD in the presence of inhibitors. (D)
Shows representative gel of VHL and the housekeeping gene gapdh. (E) VHL mRNA
expression after OGD in the presence of inhibitors. Data represent the mean and (± SD)
n=6 in all groups. *P<0.05 compared to 10U/ml EPO treated group. Inhibition of PHD-2
enhanced HIF-1 transcription in the presence and absence of EPO.
.
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Inhibition of EPO or PHD-2 alters MMP-9 Activity and Reversed
EPO’s Neuroprotection
Downstream molecule of HIF-1, MMP-9 is associated with exacerbated injury
and cells death in the acute stages of hypoxia. Thus to determine if EPO-induced HIF1

inhibition affects downstream genes expression and subsequent cell death we

assessed MMP-9 activity and cell death. According to expectations EPO treatment was
associated with lower MMP-9 activity. However inhibition of PHD-2 rapidly reversed this
resulting in significantly higher level of MMP-9 activity in PHD-2 siRNA + EPO group
compared to 10U/mL EPO and control siRNA + EPO figure 3.5.B. Alternately EPOR-FC
chimera did not appear to negatively affect MMP-9 activity in the presence of EPO.
Consequently cell death was positively correlated with MMP-9 activity. Inhibition of EPO
or PHD-2 in the presence of or absence of EPO treatment visibly reversed EPO-induced
neuroprotection compared to 10U/mL (p<0.05) EPO figure3.5.C.
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Figure 3.5. The effects of EPO treatment on MMP-9 activity and subsequent cell
death after OGD. (A) Shows representative gel of MMP-9 activity (light bands). (B)
Densiometric quantification of MMP-9 activity as detected via gelatin zymography. (C)
Shows cells death assessment via ELISA. Data represent the mean and (± SD) n=6 in
all groups. *P<0.05 compared to 10U/ml EPO treated group. #P<0.05 compared to
untreated. Inhibition of PHD-2 significantly increased MMP-9 activity and cell death with
and without EPO.

81

Discussion
Our findings showed that EPO-induced inhibition of HIF-1 which was associated
with elevated transcription and translation of PHD-2. Inhibition of EPO had prompted an
increase in HIF-1 protein expression but had no effect on mRNA. EPO-induced
elevation of PHD-2 was coupled with reduced ROS formation, MMP-9 and cell death.
HIF-1 and-2 shares 40% homology. HIF-2 has been shown to bind to the
beta subunit of HIF-1during hypoxia (Krieg et al., 2000). An accumulation of HIF-1 or
HIF-2 during hypoxia is tissue dependant. The specific HIF in neuronal tissue is still
highly debate (Yeo et al., 2008). However in our study a profile of both HIFs revealed
that, HIF-2 protein expression in cells was relatively unchanged during OGD with or
without EPO treatment. This inferred that HIF-1 and not HIF-2 is the primary HIF
associated with hypoxia in NGF differentiated PC-12 cells. On the contrary HIF-1 was
notably increased by OGD and diminished with EPO treatment. Reduction of HIF1protein expression by the administration of exogenous EPO was not previously
shown and thus warranted further investigation. EPO is a downstream gene of HIF-1
(Semenza, 1998).Therefore; we speculated that the apparent EPO-induced inhibition of
HIF-1 was probably caused by a negative feedback inhibition. However a profile of the
primary regulators of HIF-1 degradation, PHD-2 and ROS alluded to a much more
complex mechanism.
PHDs are oxygen sensors that use oxygen as a co-substrate and 2-oxoglutarate
and iron as cofactors. Because of the iron dependence iron compounds could be used
for hypoxic mimicry (Cioffi et al., 2003; Lieb et al., 2002). PHDs are extremely sensitive
to low O2 concentration which is ideal for oxygen sensing (Epstein et al., 2001b; Hirsila
et al., 2003b). They are dioxygenases that catalyze oxygen-dependent hydroxylation of
HIF-1α prolyl residues. PHD-2 promotes the degradation of both HIF-1and HIF-2

82

(Chang et al., 2005). Thus it was not surprising when we observed an inverse correlation
between HIF-1 and PHD-2 protein expression after hypoxia (figure 3.1. and figure 3.3)
and a marked increase in ROS formation that mirrored HIF-1 expression. Our data
corroborated published reports that, reduced oxygen or increased ROS allows for the
stabilization and accumulation of HIF-1 (Cash et al., 2007b; Evans et al., 2005b;
Kamura et al., 1999b; Lisztwan et al., 1999b; Stebbins et al., 1999b) . Low levels of
oxygen or high levels of ROS promotes the destabilization of PHD-2 (Cash et al., 2007c;
Epstein et al., 2001a; Evans et al., 2005a; Jones & Bergeron, 2001b). However contrary
to our expectation there were no notable changes in extracellular pH or electrolytes:
Ca2+ and K+. Despite this observation we are unable to say conclusively that EPOinduced inhibition of HIF-1 is independent of electrolytes regulation, because it is
possible that the change were too small to be detected in the media. Studies have
shown that prolyl hydroxylation and acetylation, modulates cellular HIF-1 levels by
governing the physical interaction between HIF-1α and VHL. VHL binds with elongin B,
elongin C, Rbx1 and Cul2 to form the E3 ubiquitin ligase. The ubiquitin is unable to bind
HIF-1 during hypoxia because HIF-1lacks hydroxylation or acetylation at this time
(Ivan & Scaiano, 2003b; Jaakkola et al., 2001a). Thus, we anticipated that EPO-induced
inhibition of HIF-1 would reflect corresponding increase in regulatory proteins PHD and
pVHL expression but would not alter mRNA levels. On the contrary pVHL protein
expression was almost undetectable in all groups (data not shown) and is therefore
inconclusive. HIF-1 protein but not mRNA levels were significantly reduced by EPO
treatment. This suggests that EPO-induced inhibition of HIF- is not a direct action at the
transcriptional level. Thus changes in HIF-1protein expression was mediated by either
physical interaction of EPO with HIF-1 or by transcriptional regulation of a HIF-1
regulator. Thus, we were not surprised when we observed that EPO treatment
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propagated increased in both transcriptional and translational levels of PHD-2. This
alluded to modulation of PHD-2 levels as the primary mechanism by which exogenous
EPO inhibits HIF-1 in NGF differentiated PC-12 cells during hypoxia ischemia which is
associated with neuroprotection. Conversely Ratan and colleagues showed that
inhibition of PHD and activation HIF-1 was associated with neuroprotection in vivo and
in vitro (Ratan et al., 2008; Lee et al., 2009; Siddiq et al., 2009). The apparent
contradiction in these reports attests to the biphasic nature of HIF-1 which can be
beneficial as well as detrimental (Calvert et al., 2006; Halterman & Federoff, 1999; Leker
et al., 2004). The dichotomy of HIF-1neuroprotection is best explained by Baranova
and colleagues who described an oscillation of HIF-1 levels following hypoxia ischemia.
Transient increases in HIF-1 within the first 24 hours after an injury was associated with
elevation of proapoptotic genes however, downstream prosurvival genes of HIF-1
were upregulated with later (>24hrs) sustained elevation of HIF-1(Baranova et al.,
2007) . Thus HIF-1 is detrimental in the acute stages of injury but beneficial in the
delayed/recovery stage of injury.
Silencing of PHD-2 prompted a notable increase in both protein and mRNA
levels of HIF-1, MMP-9 activity and resultant cell death even in the presence of EPO
treatment. These observations lends to the conclusion that PHD-2 is a potent mediator
of EPO-induced neuroprotection in NGF differentiated PC-12 cells.
Given the direct or indirect interaction of EPO with biphasic HIF-1 and its
primary regulator PHD-2 caution should be exercised to harness the beneficial
neuroprotective effects of EPO, without triggering the detrimental effect of delayed
inhibition of HIF-1.
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CHAPTER FOUR
DISCUSSION AND CONCLUSION

Summary/Highlight of Findings
Our findings show that EPO-induced neuroprotection was mediated by both
upregulation of TIMP-1 and inhibition HIF-1α. This finding was supported by the
following observations: (1) EPO-induced neuroprotection was associated with increased
phosphorylation of the JAK-2 receptor, downstream signal transducer STAT-3 and its
transcription product TIMP-1 and significantly lower MMP-9 activity in: in vivo and in vitro
models of hypoxia ischemia. (2) Inhibition of either JAK-2 or TIMP-1 reversed the
protective effects of EPO in both models. (3) The pharmacological inhibition of JAK-2 or
TIMP-1 was associated with reduced expression of STAT-3 and downstream gene,
TIMP-1 activity and considerable increase in MMP-9 activity. (4) HIF-1 expression and
ROS accumulation were significantly reduced following EPO treatment in OGD cells. (5)
EPO- induced inhibition of HIF-1 was associated with increased PHD-2 expression and
a corresponding decrease in ROS formation, MMP-9 activity and cell death.

The State of the Field Prior to this study
Currently it is believed that EPO –induced neuroprotection is mediated by three
major pathways downstream of JAK-2 phosphorylation namely: STAT-5, PI3K/AKT and
MAPK/RAS/ERK1/2 pathways (Ruscher et al., 2002; Socolovsky et al., 1999; Ribatti et
al., 1999; Shen et al., 2010). Previous studies have shown that JAK-2 phosphorylated
STAT -5 which is then translocated to nucleus where it activates the gene transcription
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of several proapoptotic genes suchas Bcl-xL and the X-linked inhibitor of apoptosis
protein (XIAP) (Socolovsky et al., 1999). The newly transcribed anti apoptotic proteins
inhibits both caspase dependent and caspase independent cell death, by modulating
caspase 8,3 and 9 activation as well as cytochrome c transport from the mitochindria
(Siren & Ehrenreich, 2001; Siren et al., 2001b; Siren et al., 2001a). EPO bounded to
EPOR modulates calcium-calmodulin interation resulting in a calcuim influx into the cells
(Kakihana et al. 2005). Increased intracellular calcium activates the PI3K/AKT pathway.
Prosurvival protein XIAP, Bcl2 and BclxL downstream is upregulated while proapoptotic
proteins Bad and caspase 9are downregulated via PI3K/AKT activation, thereby
promoting neurrroprotection (Dhanasekaran et al., 2008). The third major pathway that is
know to play a role in EPO-induced neuroprotection is the RAS/MAPK/ ERK1/2 pathway.
Activated EPOR phosphorylates Ras which binds to c-Raf to phosphorylate MAP2
lending to the phosphorylation of ERK1/2 which in turn activates MAPK. MAPK
subsequent inhibits Bax translocation form the cytosol and promotes Bcl-2 transcription
leading to cell survival and proliferation (Arai et al., 2002; Morrison et al., 2002). Tables
4.1 and 4.2 summarized what was known in the field prior to our study.
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Table: 4.1. A Summary of Erythropoietin-induced Neuroprotection in Animal Models of Ischemic Stroke

Stroke
Model

Focal
Ischemia
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Global
Ischemia

Neonatal
Hypoxia
Ischemia

Species

Time of
Administration

Outcome Measured

Effect

Reference

Male
Long
Evans
Rats

6, 7 and 8 days
after occlusion

Neurobehavior
Lesion Volume, Tissue
Loss

Improved infarct volume and
neurological outcomes

Belayev et al. Brain
Res. 2009 Jul
14;1280:117-23.

Male
C57BL/6
mice

30 minutes
before
ischemia/ daily
for 3, 7, 14 and
21 days

Infarct Volume.
Angiogenesis. Endothelial
Cell Survival. Local
Cerebral Blood Flow
(LCBF). Apoptosis :
Caspase activities

Decrease cell death and infarct
volume 3 days after stroke.
Restored CBF 14 days after
stroke. neurovascular protection
and neurogenesis

Li et al. J Cereb
Blood Flow Metab.
2007
May;27(5):1043-54

Male
SpragueDawley
Rats

20 hr before or
20 min or 1 hr
after ischemia

Histology of neurons. Cell
Death: DNA Fragmentation

Protected CA1 neurons of
hippocampus. Decreased
neuronal death

Male
Mongolia
n Gerbils

Immediately
after
restoration of
blood flow

Brain Edema. Hippocampal
neuronal death. Brain nitric
oxide. Survival

Increased neuronal survival and
decreased brain edema.
Reduced NO levels after
ischemia

Zhang et al. J
Neurosci Res.
2006 May
15;83(7):1241-51.
Calapai et al. Eur J
Pharmacol. 2000
Aug 11;401(3):34956.

P-7
SpragueDawley
Rats

24 hours after
insult

Inflammatory effects. Brain
Weight.

Attenuated brain injury Reduced
inflammatory cytokine and
leukocytes infiltration.

Sun et al. Stroke.
2005
Aug;36(8):1672-8.

20 minutes
after insult/ Day
2,4 and 6

Infarct Volume.
Revascularization.
Neurogenesis.
Immunohistochemistry
Neurological behavior

Reduced tissue infarct volume.
Enhanced revascularization,
increased sub-ventricular zone
cell proliferation and neuronal
migration. Improved neurological
outcomes

Iwai et al. Stroke.
2007
Oct;38(10):2795803

P-7
SpragueDawley
Rats

Table: 4.2 A Summary of Erythropoietin-induced Neuroprotection in Animal Models of Hemorrhagic Strokes
Stroke
Model

Species
Male
SpragueDawley
Rats

Time of
Administration
5 minutes after
surgery/ Daily for
14 days

ICH
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SAH

Outcome Measured

Effect

References

Neurobehavior:
Histopathological
Computation of Tissue
Loss,
Immunohistochemistry for
NeuN positive cells
Neurobehavior:
Hemorrhage Volume.
Hemispheric Atrophy.
Brain Edema. Cell Death:
TUNEL staining, Caspase
Activity

Significantly Improved Neurobehavior
1 week after insult. Reduced injury
and preservation of parenchymal
cytoarchitecture.

Grasso et al.
Neurosurgery.
2009 Oct;
65(4):763-9

Better functional recovery. Reduced
brain water content. Decreased mean
hemorrhage volume and hemispheric
atrophy. Reduced apoptosis: lower
caspase activities, TUNEL positive
cells

Lee et al. J
Neurochem.
2006
Mar;96(6):172839

Male
SpragueDawley
Rats

2 hours after
surgery / Daily
for 1 or 3 days

Male New
Zealand
White
Rabbits

5 minutes after
SAH induction/
every 8 hrs for 72
hrs

Neurobehavior:
Ischemic Lesions.
Analysis of Basilar Arteries
diameter

Improved neurobehavioral outcome.
Decreased ischemic neuronal
damage. Reduced vasoconstriction of
arteries

Male New
Zealand
White
Rabbits

* Immediately
after injection of
autologous
blood.

Cerebral Angiography.
Vascular Reactivity.

Reduced cerebral vasospasm.
Augmented basilar arterial relaxation
to acetylcholine

Male New
Zealand
White
Rabbits

10 minutes after
SAH procedure/
Day 2, 4, and 6

Computed tomography
perfusion. CT angiography.
Neurological Function.
Histology

Improved neurological outcomes.
Improved cerebral blood flow and
microcirculatory flow. Improved tissue
perfusion

Grasso et al.
Proc Natl Acad
Sci USA. 2002
Apr
16;99(8):562731.
Santhanam et al.
Stroke. 2005
Dec;36(12):27317
Murphy et al. J
Neurosurg. 2008
Dec;109(6):115564.

How does our finding advance the field?
The current knowledge in the field allowed for for the use of erythropoietin in
clinical trials as neuroprotective agent in stroke therapy. However erythropoiesis,
coagulation and thrombosis were observed in some of the adult patients in one of the
primary large center clinical trial using high dose EPO over a three week period
(Ehrenreich et al., 2009). The adverse effects observed in that aforementioned study led
many veteran EPO researchers to ask is there a future for EPO in stroke therapy
(Minnerup et al., 2010)? In an attempt to answer the aforementioned question we
arrived at our study. The key mediators of EPO induced neuroprotection in vivo and in
vitro. Our findings showed that the modulation of TIMP-1, HIF-1, PHD-2 and MMP-9
are the primary modalities of EPO-induced neuroprotection. This information will prove
invaluable in prescribing EPO for stroke therapy. TIMP-1 is a prosurvival protein that is
critical for cell survival but could promote excessive proliferation of cells if overexpressed for long periods of time as was observed in cancer. The biphasic master
regulator HIF-1 has both beneficial and detrimental properties. Thus extended inhibition
of HIF-1 is also detrimental. Additionally MMP-9 is a major player in angiogenesis
which is a critical part of wound healing. Because all of the primary mediators of EPOinduced neuroprotection are biphasic the dose and time of administration of EPO are
critical to its use in stroke therapy. Thus our response to Minnerup question is that there
is a future for EPO in stroke therapy if used in moderation at modest doses for acute
administration. The figure below integrated our findings into the current body of know on
the mechanism of EPO-induced neuroprotection in stroke therapy.
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Figure 4.1. Schematic representation of how our findings fit into the current
knowledge of the signaling pathways involved in EPO-induced neuroprotection.
The primary mechanism of secondary injury due to hemorrhagic strokes is presented in
blue. One of the primary mechanism of ischemic injury in presented in red. Matrix
metalloproteinase serves as the pivotal molecule leading to pathology in both
hemorrhagic and ischemic strokes. The green, grey and tan lines show the known
signaling pathway activated downstream of Janus Kinase 2, prior to our study. The black
lines show the signaling pathway we elucidated during this study.
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Summary/Conclusion
One of the key mechanisms of EPO-induced neuroprotection in hypoxia ischemia
in vivo and in vitro is the upregulation of TIMP-1 and inhibition of HIF-1. EPO induced
an upregulation of TIMP-1 via the JAK-2/STAT-3 pathway. The upregulated TIMP-1
inhibited MMP-9 thereby conferring neuroprotection. Additionally EPO also triggered an
increase in PHD-2 transcription and translation which lead to inhibition of HIF-1 protein
expression. The primary mediators of EPO-induced neuroprotection are STAT-3, TIMP1 and PHD-2. These molecules appear to signal from two divergent pathways that
converge at the point of MMP-9. The common denominator in both pathways, MMP-9, is
a biphasic zymogen that is detrimental during acute injury but critical in wound healing.
Thus EPO-induced neuroprotection could be a double edged sword beneficial or
detrimental depending on the dose and time of administration. However the benefits of
EPO treatment in stroke therapy are tremendous and gravely outweigh the adverse side
effects of coagulation and thrombosis. Therefore, EPO should be used with cautious
optimism.

Prospective
To develop an EPO analog that lacks erythropoietic function. Dissociating the
non-hematopoietic function of EPO from the hematopoietic function for treatment of
stroke has proven to be challenging. Thus recent efforts have been made to design
pharmaceutical analogs that lack the ability to initiate erythropoiesis. Structural analogs
asialoerythropoietin and carbamylated-Epo (CEPO) both confers cellular survival and
proliferation with minimal erythropoiesis (Erbayraktar et al., 2003; Leist et al., 2004;
Adembri et al., 2008). These analogs appear to promote neuroprotection without
initiating notable erythropoiesis, coagulation and thrombosis at low doses and for short
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duration. However if the derivatives are able to withstand long treatment without the
significant side effects is still to be elucidated. Should I expand on my current study I
would elucidate the ability of EPO analog CEPO to confer neuroprotection at high doses
for extended duration and the mechanism of the proposed neuroprotection.
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